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Abstract
PREECLAMPSIA:

THE

ROLES

OF

ACUTE

INFLAMMATION

AND

INTRAUTERINE STRESS
Preeclampsia (PE) is a severe, acute disease of pregnancy affecting
approximately 8% of pregnant women after week 20 of gestation. PE is
characterized by hypertension and renal damage reflected by proteinuria and has
significant morbidity to both mother and fetus. Maternal symptoms range from
headaches, nausea, edema, to visual changes, but once maternal symptoms
present, damage to the fetus has begun. Mothers who progress untreated
through the disease can also experience a condition called eclampsia
characterized by seizure, coma, and, ultimately, death. PE-affected newborns
experience

features

similar

to

prematurity—abnormal

lung

and

renal

development, intrauterine growth retardation (IUGR), and, possibly, fetal demise.
Interestingly, it has been shown that exposure to PE in utero can lead to many
developmental problems during the progeny’s life span. While intensive research
has been dedicated to understanding the underlying pathogenesis of PE, no
cause, predictive clinical test, nor definitive treatment has been discovered.
Although many factors are presumed as causative for PE pathogenesis, literature
has indicated that acute inflammation may play a role in the development of PE.
One such inflammatory factor is C-reactive protein (CRP). CRP, although
regarded as a non-specific innate immune factor, is found to be elevated in PE
mothers prior to onset of symptoms. The presence could indicate that CRP may
play a role in the development of PE pathology. Further, CRP binds to bacterial
viii

membranes through phosphocholine residues to trigger complement and other
innate immune responses.
Similarly, phosphocholination is a cellular process wherein phosphocholine
residues are added to biological molecules via an endoplasmic reticularly
mediated enzyme, phosphocholine transferase. A recently identified neurallysecreted placental peptide and known pathogenic factor of PE, Neurokinin B
(NKB), is phosphocholinated. This post-translational phosphocholination is
thought to increase stability and binding of NKB to its Gq coupled receptor,
NK3R. It is thought that this post-translational modification is bound by CRP
thereby creating a molecular complex to preferentially activate NK3R.
In addition to investigating the pathogenic role of inflammation in PE, we are also
curious as to how intrauterine expose to PE affects cardiovascular development
in progeny. Previous literature has demonstrated that PE predisposes offspring
to adult-onset hypertension; however, the mechanism of this fetal programing
remains unknown. We hypothesize that hypertension in offspring exposed to PE
in utero results via a two hit mechanism: 1) PE-related intrauterine stress induces
epigenetic modifications in offspring, and 2) these modifications in the presence
of environmental stressor lead to hypertension. Furthermore, we postulate that
these epigenetic modifications are conserved across generations. Intrauterine
epigenetic changes, specifically decreased global methylation of renal DNA and
AT1R promoter, in offspring born to PE mothers are conserved across
generations. When combined with an additional environmental stimulus, these
changes result in hypertension. These finding posit novel mechanisms for the
ix

etiology of hypertension and provide vital screening targets to assess the risk of
hypertension in progeny.
These two approaches to PE study combine investigation of the maternal PE
insult and pathogenesis with the investigation of transgenerational hypertensive
features to progeny, we posit a global view of PE study. We not only examine
potential targets for therapeutics and preclinical diagnostic exams, we also
provide a mechanism for transmission of hypertensive features through
generations and the possibility for hypertensive risk assessment.
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Background
Preeclampsia (PE) is a very severe disease of pregnancy which affects
approximately 10 million mothers per year worldwide. Characterized by
hypertension and proteinuria during the mid-second trimester of pregnancy, PE
can result in significant fetal developmental problems and maternal morbidity.
Affected mothers can experience renal and cardiac morbidity as well as a risk for
life-long hypertension. Uncontrolled PE symptoms can result in seizure, coma,
and death. Fetal manifestations are varied and include features of prematurity,
intrauterine growth restriction, cardiac and renal malformation, and neural
developmental delay.
Despite significant research efforts over the past decades to define the
pathogenesis behind PE, no specific cause of the disease has been found.
Further, due to the pleiotropic causes of PE, neither clinical test nor treatment
has been found to halt disease pathogenesis apart from symptomatic treatment
of the mother and delivery of the fetus at earliest stage of viability. There are
thought to be many factors in the pathogenesis behind PE, further complicating
its early detection and treatment. sFlt-1 and complement cascades, intrinsic
vascular damage/malformation, and oxidative stress have all been previously
posited to initiate features of PE in animal and human models.
sFlt-1 and its Role in the Initiation and Positive Feedback Cycle in PE
Soluble fms-like tyrosine kinase (sFlt-1) is an anti-angiogenic factor which
regulates vascular formation during production of new vascular beds, as is seen
1

during placental formation. sFlt-1 is one of the most potent endogenous inhibitors
of vascular endothelial growth factor and, thereby, inhibits placental growth factor
signaling. sFlt-1 was first hypothesized as an initiator in PE after recombinant
protein infusions in mouse models resulted in similar features found in clinical
PE.1-3 Increases in sFlt-1 circulating levels have been found in women who have
growth-restricted fetal births as well as placental insufficiency. Early findings by
the Levine group demonstrated elevations of sFlt-1 in second and third trimester
of pregnancies complicated by growth restriction and PE, however, more recent
studies have also show elevations of sFlt-1 as many as five weeks prior to onset
of PE.4 Evidence indicates that transcription and release in sFlt-1 is resultant
from placental hypoxia and ischemia. The increases in this antiangiogenic factor
result in a malicious cycle causing further placental damage.
Current literature demonstrates that balance between pro- and antiangiogenic factors is crucial to proper placentation and fetal development. To
abrogate placental damage, increases in sFlt-1 are coupled with an increase in
pro-angiogenic placental growth factor (PlGF) in early placental growth stages. In
PE, it has been demonstrated that this balance shifts toward anti-angiogenesis
resulting in a decrease of placental growth.5,

6

The dysfunction of placental

growth leads to further placental hypoxia and increasing release of sFlt-1. This
malicious anti-angiogenic factor release cycle is thought to underlie the
pathogenesis of PE. However, attempts to mitigate the effects sFlt-1 have not
been demonstrated to halt the progression of PE symptomology.

2

Complement Cascades and PE
The complement cascade comprises more than 50 proteins and utilizes 3
main pathways to protect against foreign pathogens—classical, alternative, and
lectin pathways. The activation of the various pathways or development of split
products within the pathway provides innate protection again microorganisms
and assistance in the activation of intrinsic immunity. The activation of the
complement cascade is regulated by inhibitors at various stages of each
pathway. Both membrane and soluble inhibitors control activation at early and
late stages of each pathway.7, 8
In pregnancy, the fetus and placenta represent foreign tissue. The
maternal immune system functions to protect the feto-placental environment,
however, the exact mechanism has never been elucidated. In the initial stage of
pregnancy, apoptosis in the uterine wall results in decidual tissue suitable for
implantation of the embryo. Activation of the adaptive immune system
accompanies implantation, resulting in complement C3 activation to assist in
invasion into the uterine decidua. Unique to pregnancy, decidual tissues secrete
C1q, importnant for vascular formation at the decidual-embryonic interface.9,

10

This is further shown in C1q-deficient mice, which demonstrate abnormal
placentation and dysfunctional artery development within the implanted uterus.
Abnormal complement activation has been previously demonstrated to be
important in the development of PE. Previous studies have demonstrated
significant complement activation in PE compared to normal pregnancy

3

outcomes. Derzsy et al. reported that C3 is decreased in PE pregnancies while
C3 split products and C5-C9 are increased, owing to greater complement
activation within the feto-placental environment. Additionally, some studies have
associated terminal complement components (C5-9) in pregnancies resulting in
fetal growth restriction.8-11
Despite identification of complement’s role in PE, large scale studies have
not confirmed the diminution of PE symptoms by commercial complement
inhibitors. Case reports describe eculizumab, a C5 inhibitor, could provide
symptomatic relief of PE symptoms. Treatment with this inhibitor has shown
efficacy of complement inhibition in prolonging the pregnancy, lowering
hypertension, and resolving HELLP syndrome in one case.8 Clinical treatment
with this inhibitor is regarded as somewhat risky due to complement’s role in
meningococci opsonization and the potential role complement has in bacteremia.
While inhibition of C5 is safer than other complement component inhibition since
it is not at the beginning of the complement cascade, safety of drug therapy in
pregnancy must be well-elucidated prior to human subject trials.
Vascular Damage and its Role in PE
Spiral artery formation during placentation is one of the most crucial steps
in development of healthy fetuses. Normally, the process takes place over the
first two trimesters in two stages—invasion into the decidua (as aforementioned)
during the first trimester and myometrial invasion during the second trimester.
Normal spiral artery formation is characterized by dilation during the second

4

trimester decreasing the velocity of flow into the placental bed. Failure to remodel
the spiral arteries results in tonic constriction and elevated velocity of blood flow
into the placenta. This elevated velocity results in placental damage,
vacuolization, and shedding of the intrinsic trophoblastic tissue of the placenta.
Damage to the placenta results in vasoactive cytokine release and an attempt
repair of the damaged blood vessels.12-14 If remodeling of the spiral arteries fail, it
is thought that the PE cascade can occur.
Beside placental damage in PE, another hallmark of this disease is renal
damage resultant from glomerular dysfunction. Proper glomerular endothelial
structure is integral to effective filtration and reabsorption within the kidney. Renal
biopsies of women affected by PE show a few key features of damage—
endothelial edema, obliteration of the capillary spaces, and elimination of
fenestrated endothelia. Interestingly, these hallmarks are also seen in other
hypertensive disorders of pregnancy without proteinuria, indicating that this
damage may not be intrinsically specific to PE. However, it is well-characterized
that damage to the glomerulus causes renally-mediated hypertension.3,

11, 15

Additionally, damage to glomerular endothelia is known to cause imbalances in
the VEGF angiogenic cascade normally seen in PE.
Reactive Oxygen Species Cascade in PE
Related to the vascular hypothesis of PE, reactive oxygen species and
nitric oxide (NO) bioavailability are related to both PE and vasodilatation,
essential in normal placental perfusion. It is well-known that hypoxic
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environments, as found in PE hypoperfused placentas, leads to activation of
proinflammatory cytokines and activation of NADPH oxidase. It has been
reported that NADPH oxidase is much more sensitive in PE patients than normal
pregnant women. NADPH oxidase produces reactive oxygen species (ROS)
through the catalysis of available oxygen and NADPH, an energy transport
molecule. ROS production leads to vascular dysfunction through intrinsic
endothelial damage. Furthermore, uncontrolled ROS leads to imbalance of nitric
oxide (NO) signaling, important for regulation of vascular tone. The uncoupling of
NO signaling by ROS is essential to development of hypertension and failure to
rectify ROS production can lead to uncontrolled PE.2, 16
Despite identification of this pathway and its probable role in PE, attempts
to negate ROS production by antioxidants proved unsuccessful. Antioxidant
supplementation trials by the Maternal-Fetal Medicine network showed that
Vitamin C and E supplementation failed to reduce PE symptom onset in at-risk
mothers. Examination of other important antioxidant pathways, superoxide
dismutase, catalase, and glutathione peroxidase, all have been demonstrated to
be decreased in PE mothers versus normal pregnant mothers. However, neither
supplementation trial nor medication has been developed to stimulate these
pathways.
Role of Uterine Environment in Fetal Programming
As aforementioned, if untreated, PE has devastating effects on the
mothers and fetuses. A growing body of evidence also investigates the role of

6

pregnancy-related stress and patterning effects on the fetus. It is hypothesized
that outside of the known genetic effects on the fetus, the maternal uterine
environment can developmentally pattern the fetus and predispose offspring to
lifelong health problems. Data suggests that maternal uterine stress, obesity, and
metabolic derangements can all have deleterious effects on the fetus including
hypertension, cardiac disease, and metabolic pathway dysfunction. These
patterning changes can occur on multiple levels—DNA methylation changes to
alter genetic expression, RNA translation modifications, variations in hormone
expression. These varied changes can all have deleterious effects within the
developing organism. Moreover, epidemiologic evidence suggests that these
changes can pass from generation of progeny to the next, affecting subsequent
generations after initial insult.17-22 The mechanism behind the transgenerational
passage of patterning features has not been thoroughly investigated.
The body of work presented here aims to investigate the central role of
innate immunity in PE and propose a mechanism behind progeny patterning in
the setting of pregnancy related stress.

7

CHAPTER I:
Neurokinin 3 receptor and phosphocholine transferase: missing factors for
pathogenesis of C-reactive protein in preeclampsia
Work included from:
Parchim NF, Wang W, Iriyama T, Ashimi OA, Siddiqui AH, Blackwell S, Sibai B, Kellems
RE, Xia Y. Neurokinin 3 receptor and phosphocholine transferase: missing factors for
pathogenesis of C-reactive protein in preeclampsia. Hypertension. 65(2): 430-9. (2015)
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Introduction
Preeclampsia (PE) Symptomology and Diagnosis
Preeclampsia (PE) is a serious disease of pregnancy affecting
approximately 8% of all US pregnancies and accounts for 50,000 deaths
worldwide. The key features of PE are hypertension and proteinuria after the 20th
week of gestation. The increased monitoring and therapy of these women
account for almost $70,000 in increased healthcare spending per case. More
importantly, in spite of intensive research efforts and increased focus on
prevention and treatment, neither definitive testing nor therapy has been found
for PE. Currently, the only curative solution for PE symptoms is to deliver the
fetus. PE presents significant acute and chronic risks for the mother—renal
damage,

cardiac

damage,

progression

to

seizure,

coma,

and

death.

Furthermore, PE also presents risk to fetuses exposed in utero—intrauterine
growth restriction (IUGR), features of prematurity, abnormal heart and lung
development—which predispose the fetus to cardiovascular risk later in life.23
Therefore, understanding the mechanisms underlying PE is extremely important
for early detection, as well as safe and effective therapy to treat this disease.
In recent years, increased focus has aimed toward pre-symptomatic
diagnosis of PE and prevention. Currently, in high-risk patients suspected of a
PE diagnosis, clinicians may analyze a PE laboratory panel—complete blood
count, blood urea nitrogen, creatinine, and liver function markers. Analyzed
together, these markers are sensitive for suspected diagnosis. Recent studies
indicate that inflammatory, placentally-derived, and immune biomarkers may
9

serve as potential factors in better screening and pre-symptomatic diagnosis.
Thus, the focus of our study was to examine various implicated in the
development of PE, as well as how PE is propagated through generations of
people.
Immune and Inflammatory Factors Underlie PE
Previous studies have implicated both autoimmune and inflammatory
dysregulation as underlying the pathogenesis of PE. Over the past decade,
literature has characterized autoimmunity as being fundamental in the
pathogenesis of PE. The autoimmune factor, the activating autoantibody against
the angiotensin II type I receptor (AT1-AA), has been isolated from PE patients
and extensively characterized. Pathologic activation of the angiotensin II type I
receptor (AT1R) has been shown to precipitate hypertension and renal damage
in patients with this circulating antibody.10,

24-26

It is known that the renin-

angiotensin-aldosterone system (RAAS) must be tightly regulated to account for
homeostatic blood pressure regulation. The presence of AT1-AA in the sera of
PE patients is linked with pathologic activation of the RAAS, as well as
derangement of blood pressure control mechanisms.
AT1-AA and the RAAS have been very well characterized in both human
and mouse models. AT1-AA has been shown to bind the second extracellular
loop of the AT1R, causing activation of this Gq-coupled receptor. Activation of
this receptor initiates a cascade of calcium influx and secondary messaging
signaling pathways within the cell. First characterized within the past decade,
AT1-AA has been shown to correlate with PE severity, IUGR, placental ischemia
10

and insufficiency, and maternal morbidity. Moreover, AT1-AA is thought to lead to
immune activation in both human and animal models. The reduced uterine
perfusion pressure (RUPP) rat model has shown dysregulations in various
proinflammatory cytokines—TNF-α, IL-6, IL-17, and CRP27-40—in the presence of
AT1-AA. Furthermore, an adoptive transfer mouse model involving AT1-AA
precipitates PE features in a pregnant murine system. The adoptive transfer
model also precipitates other features common in PE patients, immunologic
dysregulation. The presence of AT1-AA in the murine model also initiates a
cascade of innate immune factors. Elevations of TNF-α and IL-6 primarily
contribute to immunologic cascades and subsequent activation of the adaptive
immune system.
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Figure 1-1. Cascade of immune factors predispose PE.
Research has demonstrated that IL-6 is a potent signaling factor for the
transcription and release of CRP. Furthermore, pathologic activation of the AT1R
by AT1-AA involves TNF-α signaling and activation of the innate inflammatory
signaling cascade. While this pathway has been well-elucidated in previous work,
we encounter a significant knowledge gap with the action of CRP. The presence
of CRP in this cascade presents a novel question in the pathogenesis of PE.

12

Research has demonstrated AT1-AA and TNF-a as integral in the
pathogenesis of key features of PE—hypertension, renal damage, and IUGR.
These elevations also can precipitate a concurrent elevation of IL-6, a key
initiator of CRP transcription and release. A significant knowledge gap exists in
describing how CRP is involved in this inflammatory cascade and how it
functions in the pathogenesis of PE.
C-Reactive Protein (CRP) and its role in PE
Innate immune factors have long been postulated to be important in the
pathogenesis of PE. One immune factor, CRP, has been disputed as contributory
to PE pathology. CRP is a pentamer joined by noncovalent bond, with each
monomer sized approximately 26 kDa. Viewed axially, CRP has two faces which
assist in its innate immune actions. One side binds with bacterial membranes,
damaged cell membranes, foreign pathogens, while the other side communicates
with complement proteins to assist in the opsonization process. Activation of the
complement pathways assist in subsequent activation of adaptive immune
components.41-43 Furthermore, one of the main stimuli for synthesis and release,
IL-6, is involved in signaling many other proinflammatory factors. Because of its
nonspecific actions, CRP was not assumed to be important in PE pathogenesis.
Although initially assumed to be uninvolved in PE pathogenesis, CRP has
recently been implicated as a pathogenic factor in many different diseases.
Although mainly synthesized and secreted from hepatocytes, CRP elevations are
linked to elevated cardiovascular risk and likely lead to disease pathogenesis via
inappropriately targeting host tissues or recruiting immune cells to sites of injury.
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Persistent elevations in CRP are associated with atherosclerosis secondary to
intimal arterial damage.42-46 This kind of damage can occur by foam cell
formation and exacerbation of an atherosclerotic lesion. Of importance, CRP
elevations have also been noted in PE patients and linked to symptom
severity.47-49 While studies are conflicted about the elevation of CRP early during
pregnancy course,50-53 some have indicated elevations of CRP prior to the onset
of PE.54,

55

This indicates that CRP may serve as a predictive biomarker of PE

onset. However, the functional role of CRP in the pathogenesis of PE remains a
mystery.
Role of the Kinin Signaling Pathway in PE
Previous research behind the pathogenesis of PE has led to the
hypothesis that this disease is one involving many factors and pathways.
Recently, the kinin signaling pathway has also been thought to be involved in
disease progression. One member of this pathway, neurokinin B (NKB), was
shown to be elevated in PE patient’s sera in late diagnoses of PE. NKB is a short
13-residue neurally secreted peptide.56-58 Earlier studies on the action of NKB
have identified three primary receptors which the peptide is able to bind—the
neurokinin 1 (NK1R), neurokinin 2 (NK2R), and neurokinin 3 (NK3R) receptor.
These three receptors have shown to produce pleiotropic actions depending on
the tissue in which they are most prevalent. Significantly, NK3R activation on
vascular

beds

can

produce

vasoconstriction

and

increased

systemic

resistance.56, 59 However, the actions of NKB on other receptors may counter the
actions at the NK3R.
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To increase specificity and preferential action at the NK3R, one study
investigated a possible mechanism to explain specific activation of the NK3R.
Posttranslational modification (PTM) is an indispensable mechanism to regulate
cellular and systemic functions. Modifications such as phosphorylation,
glycosylation, ubiqutination, methylation, and acetylation are common and
necessary PTM to regulate cellular pathways. These modifications are necessary
to amplify or diminish the activity of a biological molecule or alter ligand-receptor
binding. One such PTM, phosphocholination, is thought to be involved in NKB
preferential activation of the NK3R.60 Interestingly, phosphocholinated NKB is
thought to only be found in two tissues, placenta and testis, indicating its possible
relevance to our study. Furthermore, specific activation of the NK3R is thought to
be important for the development of hypertension in pregnancy via activation of
the Gq-coupled transmembrane NK3R.61
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Materials and Methods
Human Subjects
Human materials were acquired from normal pregnant women (NT) and
preeclamptic patients (PE) admitted to Memorial Hermann Hospital which were
identified by the Obstetrics and Gynecology faculty of the University of Texas
Medical School at Houston, or from nulligravid women (NG) with no significant
past medical history in a gynecologic clinical setting. Patients were stratified to
diagnoses of severe preeclampsia, mild preeclampsia, or normotensive based on
blood pressure criteria set forth by the National High Blood Pressure Education
Working Group (2000). Patients were classified as preeclamptic based on the
presence of systolic blood pressure ≥ 140 mmHg, diastolic blood pressure ≥ 90
mmHg and presence of proteinuria ≥ 300 mg/24 hr. Further stratification for
severe PE was based on the presence of systolic blood pressure ≥ 160 mmHg or
diastolic ≥ 110 mmHg (NHBPEWG; 2000). Patients identified by research staff
were consented and enrolled in a collection study. Patient blood was collected in
EDTA and silicone collection tubes. The blood inside the silicone tubes was
allowed to clot, meanwhile, the EDTA tubes were centrifuged at 2500xg for 15
minutes. After clotting, the silicon tubes were then centrifuged at 2500xg for 15
minutes. All plasma and sera was collected and stored at -80°C. The research
protocols, consent forms were approved by the University of Texas Committee
for the Protection of Human Subjects (HSC-MS-04-384). Human subject data are
summarized and included in Table 1.
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Table 1. Patient Characteristics
NG

NT

PE

Age

26.2 ± 5.6 yr

30.4 ± 7.35 yr

27.2 ± 6.66 yr

N

21

15

15

Caucasian

48

33

27

African American

10

40

47

Hispanic

33

27

19

Other

9

0

7

BMI

24.9 ± 5.6

31.352 ± 8.38

39.305 ± 8.48

Gestational Age

NA

38.4 ± 0.99 wk

36.3 ± 2.42 wk

Systolic Max

118.0 ± 11 mmHg

124.1 ± 11.68

163.2 ± 25.99

mmHg

mmHg

72.4 ± 9.75 mmHg

100.3 ± 22.01

Racial
Distribution (%)

Diastolic Max

75.0 ± 7 mmHg

mmHg
Proteinuria

<300 mg/dL

<300 mg/dL

>300 mg/dL

Fetus Weight

NA

3200.4 + 474.5 g

2140.5 ±
867.86 g

*NG, nulligravid; NT, normotensive; PE, preeclamptic; BMI, body mass index.
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Animal Models
Pregnant C57BL/6 mice were obtained from Harlan Laboratories on
embryonic day 13 of gestation (E13) and injected with 75 μg/mL of recombinant
CRP (R&D/Tocris, Bristol, UK) on E13/E14. Eight week old nonpregnant mice
were also injected with 75 μg/mL of recombinant CRP.

In addition to CRP,

pharmacologic and siRNA knockdowns of the kinin system were used in the
model. The specific NK3R antagonist SB222200 (2.5 μM; R&D/Tocris, Bristol,
UK) was coinjected with CRP. All injection volumes were normalized to 100 μL
total volume. Alternatively, an in vivo siRNA knockdown method (Altogen
Biosystems, Las Vegas, NV) using nanoparticles was used to surround ~150 μg
of specific NK3R and/or PCT siRNA constructs (Sigma; Santa Cruz Biosciences,
St. Louis, MO; Dallas, TX, respectively). siRNA constructs were validated by
companies in terms of knockdown efficiency and multiple constructs were pooled
to achieve the most efficient knockdown strategy. Injections were prepared w/v
5% glucose to 100 μL volume according to the Altogen protocol. Mice were
injected IV via retro-orbital injection methodology with ≤ 100 μL injection volume
per inferior orbital vein. Mice husbandry care was undertaken by Center for
Laboratory Animal Medicine and Care (CLAMC) and Animal Welfare Protocol UT
AWC-11-073/14-090.
Measurement of Blood Pressure and Proteinuria in Mice
The systolic blood pressure of all mice was measured at the same time
daily by a carotid catheter-calibrated tail-cuff system (CODA, Kent Scientific,
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Torrington, CT), and the mice were kept warm using a warming pad (AD
Instruments Co, Colorado Springs, CO). Blood pressure was recorded and
averaged over a 20-min period. For the measurement of proteinuria, urine was
collected for analysis using metabolic cages (Nalgene, Rochester, NY). Total
microalbumin and creatinine in the urine were determined by using ELISA kit
(Exocell, Philadelphia, PA) and then the ratio of urinary albumin to creatinine was
calculated as an index of proteinuria.
Immunohistochemistry/Immunofluorescence
Tissues were paraffin fixed and sectioned using standard 5 µM sections
and

mounted

onto

glass

immunohistochemistry/immunofluorescence

slides.
protocol,

To
all

slides

begin
were

deparaffinized using a standard deparaffinizing protocol. Tissue sections were
marked with wax pens and blocked for 30 minutes using a standard blocking
reagent (Vector Labs, Burlingame, CA). Anti-human and anti-mouse primary
antibodies were diluted 1:50-1:200 in blocking buffer and incubated in a
humidified chamber overnight at 4°C. Slides were washed in phosphate buffered
saline and subsequently incubated in secondary antibody raised against the
primary antibody host at room temperature for 30 minutes (Vector Labs,
Burlingame, CA). Slides were then incubated with an alkaline phosphatase
substrate mixture for 45 minutes (Vector Labs, Burlingame, CA). Slides were
developed using a dual alkaline phosphatase/fluorescent development solution
(Vector Labs, Burlingame, CA). Slides were counterstained with hematoxylin and
differentiation solution. All slides were mounted with a 4’, 6-diamidino-219

phenylindole (DAPI) antifade solution (Life Technologies, Grand Island, NY) and
sealed. Images were taken with Olympus BX-60 microscope and camera. All
fluorescent images were digitally aperture standardized
Western Blotting
Presence of CRP was analyzed by previously described western blotting
procedures. To confirm expression within the tissue, all tissues were cut to ~50
mg and homogenized in RIPA buffer with protease inhibitors (Santa Cruz
Biotechnologies, Dallas, TX). Protein concentrations of tissue lysate were
measured by BCA assay (Pierce). To analyze by western blotting, 20-40 ug of
protein were loaded onto 4-20% stacked SDS-PAGE gels (Bio-rad, Hercules,
CA) and transferred onto Polyvinylidene Fluoride (PVDF-FL) membranes
(Millipore, Billerica, MA). Membranes were probed with anti-human or –mouse
primary antibodies raised against CRP in 1:500 dilutions (Abcam, Abbiotec;
Cambridge, UK, San Diego, CA, respectively). A 43-kDa actin (Sigma, St. Louis,
MO) housekeeping antibody was used as a loading control. Fluorescent
conjugated secondary antibodies were used for visualization of the membrane on
LICOR imaging systems (LICOR, Lincoln, NE).
Placental Villus Explant Culture
Placental tissue from NT patients was obtained within 20 minutes of
placental delivery. Placentas were transported on ice and prepared for
processing. Placental tissue was isolated from the periphery of the placenta
subcapsularly. 50 mg segments of placenta were perfused in DPBS, and then
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rinsed 2x in phenol red free Dulbecco’s Modified Eagle Medium (DMEM) (10%
FBS; 1% Pen-Strep). Placenta segments were manually separated using
scissors and forceps and incubated overnight at 37°C/5% CO2 in phenol red free
DMEM in 12-well plates. Villi were then treated with CRP or various antagonists
or siRNA treatment via nanoparticle encapsulated siRNA constructs prepared as
previously described in the “animals” method section. Placental villus explants
and tissue culture media was then harvested after a 48 hour period and stored at
-80°C.
Enzyme-linked Immunosorbent Assay (ELISA)
Determination of CRP and sFlt-1 levels were quantified by commercially
available ELISA kits. Human sera and/or plasma were diluted 100-fold (human
CRP,Life Technologies, Grand Island, NY; murine CRP, Exocell, Philadelphia,
PA) or 4-fold (NKB; RayBiotech, Norcross, GA). sFlt-1 (R&D Tocris, Bristol, UK)
was detected in either murine sera or placental villus explant culture media. For
microalbumin/creatinine quantifications, murine urine was diluted 13-fold
(albumin) or 20-fold (creatinine) for quantification by Exocell albuwell and
creatinine companion kits.
Quantitative Real Time-PCR
RNA was obtained from human and mouse placentas via RNeasy Mini Kit
(Qiagen, Venlo, Netherlands). RNA was transcribed into single-strand cDNA with
use of a reverse transcription kit (Qiagen, Venlo, Netherlands). cDNA was
analyzed by qRT-PCR using SYBR green (Qiagen, Venlo, Netherlands) via
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specific primers to assess mRNA relative copy counts in the sample (Table 2).
Results were calculated using 2-ΔCt method using actin as housekeeping gene
for ratio comparison.62

Table 2. qRT-PCR Primers

Primer

Sequence (5'→3')

hCRP For

AGG CCC TTG TAT CAC TGG CAG CA

hCRP Rev

CCA TAG CCT GGG GTG GCC CTT A

mPCYT1B
For

GTC ACG CAA GGG CAC TTA TG

mPCYT1B
Rev

GAG TAA GGT CAT CAC TGC AAA CT
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Histologic Analysis
The kidneys and placentas of mice were formalin fixed and processed
according to standard protocols. The tissues were sectioned in 5 µM serial
sections and were stained via hematoxylin and eosin by standard pathology
protocol. Glomeruli and placenta were examined by single-blinded study.
Number and scoring of glomeruli was assessed by counting and averaging the
number and score of glomeruli per 10 random high powered fields (40x
magnification). Scoring was based on glomerular health: (1) corresponded to
decreased bowman capsule space, intraglomerular loop dilation, and tubular
dilation; (5) corresponded to adequate bowman capsule space, no loop dilation,
and normal tubule diameter. Further description of glomerular scoring is provided
in Zhang, et al., 2013.63, 64 Placenta calcification quantification was assessed by
quantification of calcifications under 10 high powered fields. Both sets of
quantification were performed via blinded analysis using Image Pro Plus
software.
Statistical Analysis
All data were statistically analyzed with use of Graph Prism Pro v5.0, and
the data were subjected to student’s t-test (paired and unpaired), two-way
ANOVA, and Tukey’s test, where appropriate. Accepted variance was
standardized to p < 0.05. Data were graphed on Graph Prism Pro v5.0 or
SigmaPlot, where appropriate.
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Results
CRP is elevated in PE human patient samples
Aberrant innate immune factors are thought to underlie the pathogenesis
of PE. Previous literature has demonstrated that aberrant inflammatory
upregulation is integral in the pathogenesis of PE. To assess the inflammatory
status of PE patients, we began by examining levels of CRP within our PE
human patient population. Given that CRP is thought to be elevated prior to the
onset of PE symptoms, we measured CRP levels to determine elevated levels up
to delivery of the fetus. Using ELISA assays, we assayed CRP levels in patient
sera from term delivery. We also utilized a normotensive nulligravid patient
cohort as control. We observed a 3-fold increase in CRP levels in PE patients
versus NT patients with term pregnancies. Additionally, CRP levels were found to
be below the threshold of assay detectability in nulligravid patients (Fig. 1-2).
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Figure 1-2. CRP is elevated in PE patient sera and is produced in PE patient
trophoblastic tissue
(Left) Circulating CRP in sera was detectable on average 60 μg/mL in PE
patients sera (n=15) and approximately 3-fold less in normotensive (NT) (n=15)
patients. In a nulligravid cohort (n=21), levels were below the threshold of the
assay. (Right) CRP mRNA transcripts were detected in patient placental
samples. In samples isolated from PE patients, transcripts were elevated 4-fold
than those samples isolated from NT patients. ** = p < 0.05 from NT; * = p < 0.05
from NG
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While levels of CRP were detected in sera, we wanted to investigate other
sources of CRP production. While hepatic tissue is the primary organ of CRP
production and release, syncytiotrophoblastic tissue was analyzed using qRTPCR techniques for the presence of mRNA for the CRP gene. Novelly, our group
demonstrated that PE placental tissue does transcribe the CRP gene and could
be a pathologic source of CRP production. Next, we performed western blot
analysis and found that CRP protein levels were also

increased

in

PE

compared to the NT placentas (Fig. 1-3). Moreover, immunohistochemistry and
immunofluorescence dual-staining demonstrated that CRP was localized in the
villus syncytiotrophoblast cells, around the villus border (Fig. 1-3). Thus, we
have shown that 1) syncytiotrophoblast cells in the placenta express CRP and
contribute to increased circulating CRP under normal pregnancy state; 2)
elevated placental CRP is an additional source responsible for substantial
increased CRP under PE conditions.
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Figure 1-3. CRP is elevated in PE patient placental tissue as confirmed by
immunoblotting and immunohistochemistry/immunofluorescence.
(Top panels) CRP deposition within PE placentas is significantly elevated versus
deposition within NT placentas as confirmed by immunoblotting. (Bottom panel)
CRP is elevated within the external villus syncytiotrophoblast cells in PE
placentas as confirmed by immunohistochemistry and immunofluorescence. CRP
is poorly detected in placental syncytiotrophoblastic tissue isolated from NT
placentas on immunohistochemistry and immunofluorescence. 40x magnification;
Scale bar = 100 μm
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CRP induces pathophysiology of PE in pregnant mice but not nonpregnant mice
To examine the pathogenic role of CRP in PE, we infused CRP into
pregnant C57BL/6 mice on E13 and E14 of their gestation period to achieve a
similar concentration as PE patients. Our data indicate that a pathological
concentration of CRP seen in PE patients at term (75 μg/mL; based on the upper
standard deviation detectable in our circulating CRP ELISA; Fig. 1-2) was
sufficient to cause an elevation in mean systolic pressure in CRP-infused mice
(157.08 mmHg vs. 118.99 mmHg control) (Fig. 1-4). To verify the level of CRP
injected into mice, sera was sampled at the endpoint of the experiment on E18
and measured by ELISA. We observed a mean level of 11.6 μg/mL of circulating
CRP in our mice. The level of CRP on E18 is consistent with extrapolated
predictions of two injections of 75 μg/mL on E13/14. Proteinuria was also
significantly elevated in CRP-infused mice (Fig. 1-4). Similar to PE patients, both
hypertension and proteinuria were significantly dropped to the basal levels
postpartum (Fig. 1-4).
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Figure 1-4. CRP injections into pregnant C57BL/6 mice result in key
features of PE—hypertension and proteinuria—which resolve by postpartum day 10.
(Left) 75 ug/mL IV injections on E13/E14 induced mean systolic pressure
elevation by E14.5 and dropped postpartum day 5-10. * = p < 0.05; ** = p <0.05
from CRP E17.5 (n=5-8). (Right) Microalbuminuria/creatinine ratio assayed by
ELISA was significantly increased in the mice injected with CRP but diminished
by postpartum D10. * = p < 0.05; ** = p < 0.05 vs. CRP peri-partum (n=5-8).
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Additionally, histological studies demonstrated the typical glomerular
damage featured with decreased capillary lumen space and narrowing Bowman’s
capsule space (Fig. 1-5).

Histologic glomerular scoring, indicating an overall

decrease in the health of the glomerulus in the outer renal cortical region (Fig. 15). Furthermore, histological studies showed that increased placental damage
characterized with increased placental calcification in the CRP-infused pregnant
mice (Fig. 1-5).

Altogether, we provide the first evidence that CRP infusion

directly induces pathophysiology of PE in pregnant mice as seen in PE patients.
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Figure 1-5. CRP induces renal and placental damage in a pregnant mouse
model.
(Top Left) Oil-immersion microscopy showed CRP injection resulted in impaired
glomerular histological condition. (100x magnification; scale bar = 50 μm) (Top
Right) Blinded quantification of glomerular sections revealed a decrease in
glomerular score of CRP injected murine renal histological sections (n=10 fields
per kidney; 7 animals). * = p < 0.05 (Bottom Left) Analysis of placental sections
at 20x microscopy reveals significant placental damage as reflected by an
increase in placental calcification and scarring in placentas of CRP injected mice
(Arrows: indicate placental calcification; scale bar = 200 μm). (Bottom Right)
Confirmation by random high-powered field quantifications of placental sections
(n=10 fields per placenta; 7 animals). * = p < 0.05.
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Next, to determine whether CRP-induced PE pathophysiology is
dependent on pregnancy, we infused similar concentrations of CRP into
nonpregnant mice.

The key features of PE including hypertension and

proteinuria were not observed in CRP-infused nonpregnant mice (Fig 1-6). sFlt-1,
a pathogenic factor, is predominantly produced in the placentas and known to be
induced by inflammatory factors.2, 6, 10, 34, 49, 64-69 Thus, CRP may be a previously
unrecognized factor contributing to increased sFlt-1 production in the placentas
and subsequently leading to PE. Supporting this possibility, we found that sFlt-1
levels in the sera were significantly increased in the pregnant mice with infusion
of CRP compared to the control pregnant mice (Fig.1-6).

In contrast, sFlt-1

levels were extremely low and no difference observed in the nonpregnant mice
with or without CRP infusion (data not shown). Thus, we demonstrated that CRP
is a novel pathogenic factor contributing to pathophysiology of PE including
hypertension, proteinuria, kidney and placental damage and increased sFlt-1
secretion.
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Figure 1-6. CRP injections in nonpregnant animals result in no increased
hypertension and proteinuria. In pregnant animals it also induces sFlt-1
expression and release.
(Left) Nonpregnant mice injected with equivalent CRP concentrations (n=5)
exhibited no elevation in mean systolic pressure versus nonpregnant mice
injected with IV saline (n=10). (Middle) Microalbumin/creatinine ratio was not
significantly altered in CRP injected nonpregnant mice relative to saline injected
controls. (n=5-10) (Right) sFlt-1 level in the circulation was induced by CRP
injection in pregnant mice. * = p < 0.05.
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Antagonism of NK3R or specific knockdown of NK3R attenuates CRP-induced
pathophysiology of PE in pregnant mice
Because CRP binds with phosphocholine and phosphocholinated NKB
(PC-NKB) preferentially activates NK3R, it is possible that CRP-induced
pathophysiology is dependent on NK3R activation. To test this intriguing
possibility, we treated CRP-infused mice with or without NK3R specific inhibitor,
SB222200.

We found that SB222200 treatment significantly reduced mean

systolic pressure and proteinuria in CRP-infused pregnant mice (Fig 1-7).

34

Figure 1-7. CRP-induced hypertension and proteinuria is attenuated by
competitive NK3R inhibitor or in vivo siRNA knockdown of NK3R.
(Left) Co-injection of SB222200 prevented CRP induced mean systolic pressure
of pregnant mice when administered on E13/E14. Administration of nanoparticleencapsulated siRNA with CRP on E13/14 also reduced the CRP induced mean
systolic pressure of the pregnant mice. * = p < 0.05 CRP + scrambled vs. CRP +
siNK3R and CRP + SB222200; (n=5-8). (Right) Cotreatment with either
SB222200 or NK3R siRNA reduced microalbuminuria/creatinine ratio. * = p <
0.05
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There was a marked reduction in glomerular damage as indicated by an
overall improvement tubular diameter, Bowman’s capsule diameter and
glomerular scoring (Fig. 1-8). We also observed a decrease in placental
calcifications of CRP-infused pregnant mice with SB222200 treatment (Fig. 1-8).
To further validate our pharmacological studies, we performed an in vivo
knockdown of the NK3R via encapsulation of siRNA specific for the NK3R by a
nanoparticle delivery system (Altogen). First, we demonstrated that siRNA
specific for NK3R significantly reduced more than half of NK3R protein levels in
the placentas compared to the scrambled siRNA in the CRP-infused pregnant
mice (Fig. 1-8). In contrast, the efficiency of knockdown of NK3R in the kidneys
was less evident compared to the placental tissues. Thus, we concluded from
these results that siRNA specifically for NK3R successfully reduced NK3R in the
placentas but not kidneys in the CRP-infused pregnant mice. Next, we found
that knockdown of NK3R more than half by specific siRNA was sufficient to
attenuate mean systolic pressure and proteinuria in CRP-infused pregnant mice
compared to the pregnant mice with nanoencapsulated scrambled RNA (Fig. 18). Furthermore, CRP-induced placental calcifications, kidney damage and
increased circulating sFlt-1 levels were significantly attenuated by specific NK3R
siRNA knockdown in pregnant mice (Fig. 1-8). Thus, both pharmacological
studies using specific NK3R antagonist and quasi-genetic studies using siRNA to
specific knockdown of NK3R provide strong in vivo evidence that CRP-induced
PE pathophysiology is signaling via NK3R.
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Figure 1-8. Antagonism of NK3R or siRNA knockdown for NK3R attenuates
CRP-mediated renal and placental damage.
(Top

panels)

Glomerular

damage

was

significantly

attenuated

by

coadministration of SB222200 or NK3R siRNA as shown by H&E stained renal
sections. (100x magnification; scale bar = 50 μm) (Middle panels) Placental
damage was attenuated by cotreatment of SB222200 or NK3R siRNA, as
indicated by reduction of placental calcifications and scarring shown on H&E
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placental sections. (20x magnification; scale bar = 200 μm) (Bottom left panel)
Histologic scoring of glomerular damage based on double-blind scoring criteria
(n=10 fields per kidney; 7 animals). (Bottom right panel) Quantification of
placental calcifications based on blinded image analysis (Arrows: indicate
placental calcification; n=10 fields per placenta; 7 animals). * = p < 0.05
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Finally, treatment with SB222200 decreased CRP-induced sFlt-1 levels in the
pregnant mice (Fig. 1-9).

Figure 1-9. Antagonism with NK3R pharmacologic antagonist or siRNA
knockdown of NK3R attenuates sera sFlt-1 levels
sFlt-1 production is significantly attenuated in pregnant mice with coadministration of SB222200 or siRNA for NK3R. * = p < 0.05
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Knockdown of phosphocholine transferase ameliorates CRP-induced PE
features in pregnant mice
Because NKB is modified by placental phosphocholine transferase (PCT)
(i.e. PCYT1b) and PC-NKB preferentially activates NK3R, it is possible that CRPmediated activation of NK3R and subsequent disease development are
dependent on the placental PCT. To overcome the difficulty of lack of a potent
and specific inhibitor for PCT, we performed quasi-genetic studies using
nanoparticle encapsulated siRNA specifically to knockdown the synthesis of this
important enzyme in CRP-infused pregnant mice. First, we confirmed that siRNA
specific for PCT significantly reduced mRNA of this enzyme in the placentas of
CRP-infused mice compared to the scrambled siRNA (Fig. 1-10). Additionally,
knockdown of PCYT1b by specific siRNA for PCT significantly attenuated mean
systolic pressure and proteinuria in the CRP-infused pregnant mice versus the
CRP-infused pregnant mice injected with scrambled siRNA (Fig. 1-10).
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Figure 1-10. In vivo siRNA knockdown of phosphocholine transferase
attenuates mean systolic pressure and proteinuria.
(Left) Confirmation of knockdown is shown by qRT-PCR on placental lysates
(n=5). Administration of nanoparticle-encapsulated siRNA for PCYT1b with CRP
on E13/14 reduced the mean systolic pressure of the pregnant mice. * = p < 0.05
(Right) Cotreatment of PCYT1b siRNA reduced microalbuminuria/creatinine ratio.
* = p < 0.05
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Furthermore,

CRP-induced

placental

calcifications,

kidney

damage

and

increased circulating sFlt-1 levels were significantly attenuated by specific PCT
siRNA knockdown in pregnant mice (Fig. 1-11). Thus, quasi-genetic studies
using siRNA to specifically knockdown PCT revealed that placental PCT, which
is a key enzyme responsible for NKB phosphocholination, is essential for CRPinduced PE pathophysiology.
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Figure 1-11. In vivo siRNA knockdown of phosphocholine transferase
attenuates renal and placental damage, as well as sFlt-1 production and
release.
(Top

panels)

Glomerular

damage

was

significantly

attenuated

by

coadministration of PCYT1b siRNA as shown by H&E stained renal sections.
(100x magnification; scale bar = 50 μm) (Middle panels) Placental damage was
attenuated by cotreatment with PCYT1b siRNA, as indicated by reduction of
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placental calcifications and scarring shown on H&E placental sections. (20x
magnification; scale bar = 200 μm) (Bottom left panel) Histologic scoring of
glomerular damage based on double-blinded scoring criteria (n=10 fields per
kidney; 7 animals). * = p < 0.05 (Bottom middle panel) Quantification of placental
calcifications based on blinded image analysis (n=10 fields per placenta; 7
animals). * = p < 0.05. (Bottom right panel) CRP induced sFlt-1 production was
significantly attenuated in pregnant mice with coadministration of SB222200 or
siRNA for PCYT1b. * = p < 0.05
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Elevated CRP and NKB are co-localized in syncytiotrophoblast cells of placentas
of PE patients
To

extend

our

mouse

findings

to

human,

we

performed

coimmunofluorescence staining to determine the localization of CRP and NKB in
the term placentas from NT pregnant women and PE patients.

Specifically, we

found that CRP and NKB were observed in the syncytiotrophoblast cells of the
maternal villi and substantially increased in the placentas of PE compared to NT
pregnant women (Fig. 5A). Additionally, co-localization of CRP and NKB was
visualized along the cellular membrane of the villus syncytiotrophoblast cells (Fig.
1-12). It is interesting to note that the CRP and NKB were extranuclear and
mainly outside of the cytoplasm of the trophoblast cells. Thus, these translational
human studies demonstrated that CRP and NKB are elevated and colocalized in
the syncytiotrophoblast cells in human placentas from PE patients.
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Figure 1-12. CRP and NKB colocalize within placental syncytiotrophoblast
cells in PE patient placentas.
Coimmunofluorescence revealed increased CRP and NKB in syncytiotrophoblast
cells in terminal villi. On the merged image, membrane colocalization was
visualized along the syncytiotrophoblast cells. Some autofluorescence can be
seen intravascularly due to the presence of autofluorescent RBCs. (40x
magnification; scale bar = 100 μm).
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CRP signaling via NK3R directly induces sFlt-1 secretion from cultured human
placental villus explants in a PCT-dependent manner
Although we showed that CRP-induced hallmark features including
hypertension, proteinuria and increased circulating sFlt-1 levels in an intact
animal by activating NK3R and in a PCT-dependent manner, the pathological
role of CRP in humans remains unidentified. To test the significance of CRP in
PE in humans, we took advantage of primary cultured human villous explants to
determine if CRP signaling via NK3R contributes to PE by directly inducing sFlt-1
secretion in a PCT-dependent manner. Similar to mouse finding, we found that
CRP treatment directly induced sFlt-1 secretion from cultured human villous
explants from NT pregnant women at term (Fig. 1-13). Moreover, SB222200, a
specific inhibitor of NK3R, and siRNA specific for NK3R significantly reduced
CRP-induced sFlt-1 secretion from cultured human villous explants (Fig. 1-13).
Finally, siRNA specific for PCT also significantly reduced CRP-induced sFlt-1
secretion from cultured human villous explants (Fig. 1-13). Taken together, these
results translate our mouse finding to human pregnancy by showing that CRP
signaling via NK3R contributes to sFlt-1 secretion in a PCT-dependent manner
from cultured human villous explants.

47

Figure 1-13. sFlt-1 production is significantly attenuated in the presence of
antagonist of NK3R and knockdowns of NK3R and phosphocholine
transferase in cultured placental villus explants
Placental villus explants isolated from normal patients and treated with or without
CRP in the presence or absence of series of drugs or siRNA. CRP directly
induced secretion of sFlt-1 from cultured human villus explants, but this increase
was attenuated by treatment with SB222200 or siRNA for NK3R or PCYT1b. * =
p < 0.05 difference from control; # = p < 0.05 difference from CRP + scrambled.
(n = 4 wells placental villous explant culture)
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Discussion
CRP is increased in the circulation at early stage prior to PE symptoms
and its elevation is correlated to the disease severity. However, nothing is known
about its role in PE, the specific cell types responsible for its increased
production and the molecular basis for its function. Here we have provided
human evidence showing that CRP transcripts are present in syncytiotrophoblast
cells of normal placentas and further increased in the PE placentas, indicating
that syncytiotrophoblast cells in the placenta are a previously unrecognized
additional source for increased circulating CRP seen in PE patients. Extending
human studies we have further demonstrated the pathogenic nature of CRP in
PE by showing that injection of CRP alone is sufficient to regenerate the key
features of PE including hypertension, proteinuria, kidney damage and impaired
placentas in pregnant mice. Mechanistically, we revealed CRP signaling via
NK3R contributes to sFlt-1 secretion and disease development in PCTdependent manner in intact animals and in cultured human villous explants.
Overall, we have provided both human and mouse evidence that increased CRP
contributes to PE pathophysiology by cross-talking with PCT and NK3R. Thus,
our findings have identified the detrimental role of CRP, new sources for its
production and a novel signaling cascade for its pathogenic effects in PE. These
findings suggest novel therapeutic opportunities
CRP is predominantly produced by hepatocytes under nonpregnant
states. Prior to our studies it was unclear what specific cell type was responsible
for increased circulating CRP in PE patients. Here we demonstrated for the first
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time that placentas contain transcripts for CRP and CRP transcript levels are
significantly increased in the placentas of PE patients compared to NT pregnant
individuals. However, CRP levels are virtually undetectable in nulligravid women.
Using immunohistological studies, we further found that CRP is predominantly
expressed in syncytiotrophoblast cells of human placentas. Thus, we provide
human evidence that placental syncytiotrophoblast cell is a previously
unrecognized cell type expressing CRP and it is additional source contributing to
circulating CRP in PE patients. Understanding how CRP gene expression is
regulated under physiological and pathological pregnancy will be important
questions for us to further address.
CRP is an innate immune factor and works with complement components
to kill the bacteria and virus or remove damaged tissues. Because of its early rise
in the inflammatory process, CRP is often considered as an important early
predictor for the immune response. Although the transient elevation of CRP in
response to the presence of pathogens is beneficial, the prolonged and
persistent elevation of CRP is likely harmful resulting in damage to host
tissues.42, 43, 45, 46, 70, 71 Some studies have suggested that obesity and increasing
BMI, correlated with late-onset PE, are key factors in increasing CRP and those
cytokines instrumental in its production and release.72 However, multiple human
studies have shown that circulating CRP is elevated at the early stage prior to
clinical symptoms in PE patients and its level is correlated to the severity of the
disease.44, 47 Moreover, several studies indicate that the elevation of circulating
CRP is correlated to multiple pathogenic factors including TNF-α, IL-6, excess
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complement production and soluble VEGF, implicating its role in endothelial
dysfunction, uterine arterial constriction, macrophage activation, and arterial
plaque formation.9 However, the pathogenic role of elevated circulating CRP in
PE has not been previously examined in vivo. Here we demonstrated for the first
time that injection of CRP to achieve similar concentrations to those seen in PE
patients induced hallmark features of PE including hypertension, proteinuria,
kidney damage and placental impairment in pregnant mice. Because PE is a
pregnancy related disease, the placenta has been long considered to play an
important role in the disease development. To examine the role of placentas in
CRP-induced hypertension and proteinuria, we injected similar amount of CRP
into nonpregnant as pregnant mice. In contrast to pregnant mice, CRP failed to
induce PE features in nonpregnant mice. These findings are consistent with
reports of LaMarca and colleagues showing that TNF-α, IL-6, and IL-17 can only
induce high blood pressure in pregnant rats, not in nonpregnant rats.29, 30, 33 We
further discovered that CRP induces sFlt-1 production in pregnant mice but not
nonpregnant mice, suggesting the placenta as the source of increased sFlt-1.
Extending our mouse studies, we have demonstrated that CRP directly induces
sFlt-1 secretion from cultured human villous explants. Elevated sFlt-1 contributes
to pathophysiology of PE including abnormal placentation, hypertension and
kidney injury.3 Thus, a possible explanation for CRP only inducing PE features in
pregnant mice but not nonpregnant mice is that CRP only induces secretion of
placental derived toxic factor, sFlt-1, during pregnancy.

Taken together, our

studies revealed that elevated CRP is a potent immune mediator responsible for
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increased sFlt-1 secretion and impaired placentas. Without interference, CRPsFlt-1-placental damage functions as malicious cycle leading to progression of
the disease and symptom development (Fig. 1-14).
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Figure 14. Working Model: CRP and PC-NKB communicate with the NK3R
to elicit features of PE.
CRP is expressed in the placentas and elevated CRP in the syncytiotrophoblast
cell is additional source underlying increased circulating CRP in PE patients.
Locally-synthesized
phosphocholinated

CRP
NKB

cross-talks
(PC-NKB)

by

with

post-translationally

placental-specific

modified

enzyme,

PCT.

Subsequently, CRP and PC-NKB work together preferentially activates NK3R
leading to increased sFlt-1 production and release. Our findings reveal novel
mechanisms for pathogenesis of PE and identify innovative therapeutic
possibility for prevention and treatments.
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NKB is mainly secreted from brain and placentas. Early human studies
found that circulating NKB is significantly elevated in PE patients.57,

58, 61

More

recent studies showed that endogenous NKB is modified by phosphocholine
transferase (PCT). The phosphocholinated NKB (PC-NKB) preferentially
activates NK3R, a Gq coupled receptor. As such, elevated NKB activating NK3R
induces calcium influx and subsequent vascular hypertension and kidney
damage. During infection, CRP binds with phosphocholine on the membrane of
bacteria and virus and works with complement systems and inflammatory cells
together to eventually kill foreign invaders. Here we have provided multiple lines
of evidence supporting a novel but compelling molecular basis that under PE
condition in the absence of infection, increased CRP signaling via NK3R
contributes to PE pathophysiology in a PCT-dependent manner. First, we have
provided in vivo animal evidence that CRP-induced PE pathophysiology is
significantly reduced by blocking NK3R signaling by its specific antagonist or by
lowering its protein levels by its specific siRNA.

Subsequently, using quasi-

genetic studies to specific knockdown PCT, CRP-induced PE features in the
pregnant mice are significantly ameliorated. Thus, both pharmacological and
quasi-genetic studies provide strong in vivo functional evidence that PCT
mediated NKB phosphocholination, and NK3R signaling underlies CRP-induced
pathogenic effects in pregnant mice.
We have further validated our mouse finding and provided human
evidence showing that NKB and CRP are co-localized in membrane of
syncytiotrophoblast cells of villous human placentas and their levels were
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significantly increased in the placentas of PE patients compared to the NT.
Similar to our mouse finding, we have demonstrated that CRP signaling via
NK3R directly induces sFlt-1 secretion from cultured human villous explants in a
PCT-dependent manner. PCT is only known to be expressed in two organs
including placentas and testis. So far, two endogenous molecules are identified
to be modified by PCT, i.e., NKB and corticotropin releasing factor (CRF).60
PCT-mediated PTM of these two molecules is considered leading to PC-NKB
preferentially activating NK3R and preventing PC-CRF degradation in circulation,
respectively. Because placenta serves as the only source of PCT necessary for
posttranslational phosphocholination of NKB, PE features were not observed in
nonpregnant CRP-injected mice.

Thus, our findings support a novel working

model: increased CRP functionally coupled with PCT, a key enzyme carrying
posttranslational modification of NKB only occurring in the placentas,
preferentially activates NK3R and subsequently promote disease development
(Fig. 1-14). Interfering with these pathogenic molecules including placental
specific PCT and NK3R are promising therapeutic possibilities (Fig.1-14).
Although our results clearly show that PCT and NK3R signaling are functionally
required for pathogenic role of CRP in PE, we have been unable to demonstrate
how PCT-mediated PC-NKBs cross-talk with CRP. In view of important role of
PCT and NK3R in CRP-induced pathophysiology of PE, one of the most
reasonable possibilities is that CRP and PC-NKB directly interact and then this
complex preferentially activates NK3B and leads to PE features. Although our
human studies have showed that CRP and NKB are co-localized on the
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membrane

of

syncytiotrophoblast

cells

of

human

placentas,

our

coimmunoprecipitation pull down assay has been unable to show a direct
interaction of these two molecules. Our lack of success may reflect a weak
interaction that does not persist through such experiments or low abundance of
PC-NKB that does not allow us to pull down the complex. Nevertheless, lacking
direct evidence for the interaction of CRP with PC-NKB does not prevent us to
conclude that CRP is pathogenic for PE functioning through NK3R signaling in a
PCT-dependent manner.

Thus, the important and clear evidence of CRP

functionally dependent on NK3R and PCT

leads to several exciting new

directions including determining the molecular mechanisms by which CRP
pathogenesis requires PCT and activates NK3R signaling and developing a
specific and potent PCT and NK3R inhibitors to treat PE.
In conclusion, our findings are innovative since little was known about the
role of CRP and placental PCT in PE until data suggested that placental PCT
and NK3R are key factors responsible for CRP-induced pathophysiology of PE.
Moreover,

our

discovery

that

placentas

contain

CRP

transcripts

and

syncytiotrophoblast cells contribute to increase in circulating CRP in PE patients
are also novel.

Finally, our findings are clinically significant since we have

determined that CRP is not only an early biomarker, but it has a pathogenic role
in PE Thus, our current studies have added significant new insight to the
pathogenesis of PE, have revealed early pre-symptomatic pathogenic biomarker
and thereby have opened up novel therapeutic possibilities for the disease
prevention and treatment.
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NOVELTY AND SIGNIFICANCE
What Is New?
•

An acute inflammatory mediator, CRP, is elevated in the circulation and

placentas of women with PE. Thus, placenta may be an additional source
contributing to elevated CRP in PE
•

Injection of recombinant murine CRP into pregnant mice results in

increased sFlt-1 production, hypertension and proteinuria via cross-talk with NKB
and subsequent activation of NK3R.
•

A critical role for placenta-specific phosphocholine transferase (PCTY1b)

in the modification of NKB was identified in CRP-induced pathophysiology of PE.
•

CRP-NKB cross-talks with neurokinin 3 receptor (NK3R), increasing sFlt-1

production in cultured human placenta villous explants in an PCTY1b dependent
manner
What is relevant?
Our data reveal a previously unrecognized pathogenic role of CRP signaling via
NK3B in the pathogenesis of PE dependent on placental specific enzyme,
phosphocholine transferase, highlighting potential therapeutic possibilities.
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Summary
We report that CRP, previously thought to be a nonspecific inflammatory
mediator, is elevated in circulation of normotensive pregnant women compared
to nulligravid women and further elevated in women with PE.

Additional

experiments determined that CRP is produced by the syncytiotrophoblasts of the
placenta.

We demonstrated the pathogenic role of CRP by infusion of

recombinant CRP into pregnant mice to show features of PE, including
hypertension and proteinuria. Furthermore, by antagonism or knockdown of the
NK3R using pharmacologic or siRNA methodology, we found that this receptor is
essential for the CRP-induced features of PE including hypertension, proteinuria,
placental and kidney pathology. Additionally, we found that the placenta-specific
enzyme, phosphocholine transferase (PCTY1b), was required for the CRPinduced pathophysiology in pregnant mice. Finally, we validated our mouse
studies in human and showed that CRP induced sFlt-1 secretion by isolated
human placental villus explants via NK3R activation in a PCTY1b-dependent
manner. Altogether, our human and mouse studies reveal CRP cross talks with
NKB signaling contributes to pathophysiology of PE in a PCTY1b-depenent
manner, and thereby highlight potential therapeutic possibilities.
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CHAPTER II:
Role of Transgenerational Epigenetic Modifications of the AT1R on the
Pathogenesis of Adult-Onset Hypertension
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Introduction
Transgenerational Features of Disease
A developing field of research characterizes the role in in utero imprinting
and transmitting disease to future generations called fetal programming. Fetal
programming is encompassed into a broader field termed epigenetics. It was
previously thought that only genetic factors could affect the development of a
fetus. However, recent evidence points to the complex relationship between
genetic and environmental factors which can affect fetal development and
organogenesis.22,

73

Epigenetics concerns all changes that can affect genetic

expression above the genome. Alterations in expression occur from a variety of
mechanisms—histone modifications, RNA interference, or DNA promoter
methylation.22, 74, 75 These modifications affect the overall accessibility of the DNA
sequence and facilitate or inhibit replication and transcription. Of these
modifications, literature indicates that DNA promoter methylation is important for
transgenerational passage of epigenetic imprinting to subsequent generations.18,
76, 77

DNA promoter methylation involves modifications at the DNA promoter
level to affect transcription of the DNA. Specifically, methyl group attachment to
the C5 position of cytosine residues serves to modify individual DNA bases. The
methyl group attachment primarily occurs within regulatory sequences call CpG
islands, regions rich in cytosine and guanine (CG) base pairs.21,

78

Hypermethylation of these sequences is important for transcriptional repression
and inactivation of gene expression at certain developmental time points.
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Likewise, hypomethylation can be an equally important modification to affect
genetic expression. However, hypomethylation and its role in transcriptional
regulation is poorly investigated. It is thought that global decreases in methylation
can be precipitated by decreases in DNA methylation transferase 1 (DNMT1).79 It
is known that DNA hypomethylation plays essential roles in brain development,
cancer, and cardiovascular diseases.80,

81

However, the specific mechanisms

underlying hypomethylations in this disease processes remain a mystery.
While global hypomethylation is presumed to precipitate disease
processes, the mechanism underlying this process is undefined. One mechanism
thought to determine methylation status on promoters is in utero stress.
Preeclampsia is a type of intrauterine stress thought to predispose the fetus to
future problems. To note, women who have one pregnancy affected by PE are
more likely to have late life cardiovascular or renal disease.21,

82-84

Likewise,

progeny exposed in utero to PE have a higher incidence of cardiovascular
disease, metabolic disease, and inflammatory conditions.21,

22, 82-98

These

features are witnessed in the absence of known genetic mutations, leading to the
presumption that other mechanisms may be involved. Based on previous
literature, hypomethylation and inactivation of DNMT1 could be potential factors
in late-life hypertension.
Disturbance

of

Renin-Angiotensin-Aldosterone

(RAAS)

Signaling

as

a

Pathogenic Factor in PE and Hypertension
One of the hallmarks of hypertensive disorders is disturbances in
hypertensive signaling pathways and failures of the systems to counteract them.
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One of the drivers of hypertension and PE is disruptions of the RAAS. The
classical RAAS pathway involves signaling of pressors to counteract a
depression in blood pressure sensed by the juxtaglomerular apparatus (JGA) in
the kidney. JGA cells synthesize renin which catalyzes the conversion of
angiotensinogen to angiotensin I (Ang I). Ang I is subsequently converted to Ang
II in the lung. Ang II is a potent vasoactive peptide resulting in increased systemic
resistance and blood pressure. Ang II also signals aldosterone release which
acts on the kidneys to sequester fluid and sodium, thereby keeping the
intravascular volume high, leading to further increases in blood pressure.99-102
The entire system is counteracted by various mechanisms including alternative
angiotensin peptide isoform signaling or compensatory signaling cascades,
leading to potent vasodilation.12,

103-105

However, in pathologic conditions, the

RAAS system has been known to drive increases in systemic blood pressure
with resistance to counteracting mechanisms.
Sensitivity to Ang II is a hallmark of both PE and hypertension
pathology.14, 100, 106-108 Alterations of the methyl-transferase activity within the cell
leads to changes within the cytosine-rich segments of DNA within the promoter
regions known as CpG islands. These alterations have been studied in
hypertension. Some studies have shown alterations in the 5-methyl Cytosine
(5mC) content in the promoter region of key RAAS components—Angiotensin
converting enzyme and angiotensinogen.79, 109 While hypermethylation has been
shown to regulate ACE expression and is associated with hypertension,
hypomethylation of the angiotensinogen promoter was associated with a greater
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expression angiotensinogen and was further driven by increases in salt intake.
Furthermore, it has previously been reported that the angiotensin receptor gene
is hypomethylated in a salt-sensitive rat progeny as early as the first week
postpartum.79,

100, 106

Increased vascular sensitivity to Ang II has also been

implicated in aortic, carotid, and small vessels in Ang II-exposed previously
preeclamptic mouse and rat models.89, 100, 110 This could suggest an exaggerated
RAAS response, as well as be evidence for the importance of methylation status
in hypertension.
Link between Inflammation and Intrauterine Stress
Numerous studies have linked the pathologic activation of the RAAS to
presence of an autoantibody against the AT1R (AT1-AA). While levels of AT1-AA
are positively correlated with hypertension and renal damage in pregnancy, the
mechanism of development of this antibody has not been elucidated. While
pathologic activation of the AT1R has been linked to elevations TNF-alpha, IL-6,
ET-124, 25, 27, 28, 31-33, 35, 36, 111, it is unclear if inflammation or epitope presentation is
the stimulus for autoantibody production. Recent data has characterized the roles
of a TNF superfamily member, LIGHT, and a glutamyltransferase, tissue
transglutaminase (tTG) as necessary for production of AT1-AA.64 LIGHT-injected
pregnant mice display autoantibody production via induction of a ε-(γ-glutamyl)lysine isopeptide dimerization in the AT1R. This modification is blocked by a
specific tTG inhibitor, cystamine.112 This finding links the presence of acute
inflammation via TNF activation, tTG, and the production of autoantibody in PE
states (Luo R, under review, Hypertension).
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Given these data, we present a novel mechanism for the transgenerational
passage of epigenetic modifications and the role they play in the development of
hypertension. We outline two necessary features integral for hypertension in a
genetically homogenous mouse model. We hypothesize that hypertension
requires:
A. Exposure to intrauterine stress (i.e. preeclampsia stimulus)
B. Subsequent exposure to provasoactive substance (i.e. angiotensin II)
Through the data presented here, we show that intrauterine stress results in
initial hypomethylation of the angiotensin II type I receptor promoter within CpG
islands. Hypomethylation of this promoter leads to sensitivity to angiotensin II
exposure and drives further hypomethylation of the AT1R promoter. This
subsequently leads to increases in further AT1R expression and the failure to
rectify the hypertensive insult. We also show that the pattern of hypomethylation
can be transmitted through subsequent generations of progeny, leading to similar
phenotypes and epigenetic genotypes in their progeny (Fig. 2-1). The study
presented leads to tighter treatment of PE during the disease course and could
lead to increased prediction of the PE and hypertension based on promoter
methylation status.
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Figure 15. Hypothetical model of intrauterine stress and epigenetic modification.

We posit a two-hit hypothesis as integral to development of multigenerational AHTN. In utero stress predisposes the fetus to hypomethylation of key RAAS
genes, leading to their increased expression. Through mechanisms currently not
understood, it has been shown that methylation patterns can be transmitted to
subsequent generations. We believe that these methylation patterns, in tandem
with exposure to environmental stress, will elicit a greater response, and, thus,
cause features of hypertension.
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Methods
Mouse Model and Microosmotic Minipump Implantation
Pregnant C57BL/6 mice were obtained on E13 of gestation (Harlan
Laboratories; city). After a brief quarantine and acclimation period, baseline blood
pressure was measured via tail-cuff methodology as previously described (Coda;
Kent Scientific, Torrington, CT). Baseline mean systolic pressure was calculated
from 20 repeated cycles of the CODA machine. After baseline blood pressure,
female mice were injected retroorbitally with IgG isolated from normotensive (NT)
and preeclamptic (PE) human patients as described in Irani, et al.24, 25 Mice were
injected on E13/14 of gestation. Repeat blood pressure measurements were
performed diurnally until E18. Mice were allowed to deliver producing generation
II. Weaning occurred at post-parturition week three. Pups were subdivided and
half of the litters were bred together to produce generation III. Remaining pups
were aged for 26 weeks, during which time blood pressures were measured via
tail-cuff methodology. At 26 weeks, microosmotic minipumps (Alzet, Cupertino,
CA) programmed to deliver 140 ng/kg/min of human angiotensin II (SigmaAldrich, St. Louis, MO) were implanted in the dorsal region of the mice through a
1 cm incision sub-cranially. Mice were monitored post-operatively for infection
and recovery. Blood pressure was monitored via tail-cuff on minipump-implanted
mice on D3, 7, 10, and 13 post-implantation. Mice were subsequently sacrificed
on D14 for organ and histological analysis. Mice husbandry care was undertaken
by Center for Laboratory Animal Medicine and Care (CLAMC) and Animal
Welfare Protocol UT AWC-11-073/14-090.
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Similar protocols were performed on generation III mice.
Quantitative Real-Time PCR
RNA was obtained from mouse renal tissue isolated and frozen in liquid
nitrogen. RNA was reverse-transcribed into single-strand cDNA with use of the
Quantitect reverse transcription kit (Qiagen, Venlo, Netherlands). cDNA was
analyzed by qRT-PCR using SYBR green (Qiagen, Venlo, Netherlands) via
specific primers to assess mRNA relative copy counts in the sample. Results
were calculated using 2-ΔCt method using housekeeping gene for ratio
comparison.62
Western Blotting
Presence of AT1R was confirmed by standard wet transfer methods. To
confirm expression within the tissue, all tissues were cut to ~50 mg and
homogenized

in

RIPA

buffer

with

protease

inhibitors

(Santa

Cruz

Biotechnologies, Dallas, TX). Protein concentrations of tissue lysate were
measured by BCA assay (Pierce, Grand Island, NY). To analyze by western
blotting, 20-40 ug of protein were loaded onto 4-20% stacked SDS-PAGE gels
(Bio-rad, Hercules, CA) and transferred onto PVDF-FL membranes (Millipore,
Darmstadt, Germany). Membranes were probed with anti–mouse primary
antibodies raised against AT1R in 1:500 dilutions (Santa Cruz Biotechnologies,
Dallas, TX). An antibody to β-actin housekeeping gene(Sigma Aldrich, St. Louis,
MO) was used as a loading control. Fluorescent conjugated secondary
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antibodies were used for visualization of the membrane on LICOR imaging
systems (LICOR, Lincoln, NE).
Bisulfite gDNA Treatment and PCR Analysis
To examine the methylation content of the renal AT1R promoter, bisulfite
treatment and sequencing was utilized. gDNA was isolated from 50 mg flashfrozen kidney sections utilizing a DNeasy kit and protocol (Qiagen, Venlo,
Norway). gDNA was analyzed by spectrophotometry on a multiwell Take3 plate
and synergyHT plate reader (Biotek, Winooski, VT) and normalized to
concentration. Normalized gDNA was subsequently treated with bisulfite
compound according to the EpiJet Bisulfite protocol (Thermo Scientific, Waltham,
MA). To analyze promoter regions of the AT1R, the promoter sequence of AT1R
was analyzed by MethPrimer software. Primers were designed to target expected
CG-rich islands, based off of designated parameters.78, 89, 113 Primers to test the
methylated and unmethylated regions were designed and subsequently used in
qRT-PCR.
Sequences of designed primers used were:
5’3’ Methylated Forward AGTTTGGATTTGGAAGGGTATATC and Methylated
Reverse AACTACCTAACGATCAACAACGAA
5’3’

Unmethylated

Forward

GAGTTTGGATTTGGAAGGGTATATT

and

Unmethylated Reverse CAACTACCTAACAATCAACAACAAA.
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CpG

island

methylation

ratio

was

taken

as

ratio

of

unmethylated

amplification:methylated amplification subtracting the background of amplification
from non-bisulfite treated gDNA using the 2-ΔCt method.

Crosslinked Chromatin Immunoprecipitation Assay
Tissue extracted from mice treated with and without Ang II was flashfrozen in liquid nitrogen. ~50 mg sections were cut from the kidney and
underwent crosslinkage reaction using 1.5% formaldehyde in MeOH. Samples
were homogenized, and chromatin was isolated from the kidney sections. A
transcriptional predictive analysis examining promoter sequence homology found
that c-Jun (AP-1) transcription factor has a 87% sequence homology with the
AT1R promoter region. Based on these results, 25 µg crosslinked chromatin
isolated from the kidney sections was incubated with c-Jun antibody (Abcam,
Cambridge, UK) at a ratio of 3 µg antibody:25 ug chromatin on magnetic protein
A/G beads overnight at 4 C. Chromatin samples were washed, eluted and decrosslinked according to protocol (ActiveMotif, Carlsbad, CA). Chromatin
samples and input samples were analyzed by qRT-PCR as previously described
above.
Statistical Analysis
All data were statistically analyzed with use of Graph Prism Pro v5.0, and
the data were subjected to student’s t-test (paired and unpaired), two-way
ANOVA, and turkey’s test, where appropriate. Accepted variance was
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standardized to p < 0.05. Data were graphed on Graph Prism Pro v5.0 or
SigmaPlot, where appropriate.
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Results
Intrauterine stress PE mouse model
It is well accepted that intrauterine stress can have significant
developmental

ramifications

to

affected

fetuses.

Such

developmental

abnormalities can be observed within the renal, neurological, and, most
significantly, cardiovascular system. Our study utilizes an established model of
intrauterine and maternal stress by using an adoptive transfer model of human
AT1-AA isolated from PE patients. Previous models have demonstrated that
isolated AT1-AA injected into pregnant mice induces key features of PE including
hypertension and renal damage as well as features of intrauterine growth
restriction in the fetal milieu.24,

25, 27, 28

Our model uses these features of PE to

represent intrauterine stress and developmental delay.
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Figure 16. Model of adoptive transfer of IgG to pregnant mice on embryonic day
13/14 precipitates PE features. A transgenerational mating scheme was developed
to produce Generation I, II, and III.

Our experimental model involves isolation of IgG from both normotensive
mothers (NT-IgG) to serve as control and IgG from PE mothers (PE-IgG). IgG
was injected into mice on embryonic day 13 and 14 of gestation. Pups
(generation II) were born to affected and control mothers. Generation II mice
were monitored for growth and blood pressure. Generation II mice were interbred
to produce generation III mice and these were monitored for physiologic
characteristics in the same manner as generation.
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After parturition, baseline characteristics were measured in the pups and
examined for significant phenotypic differences (Fig 2-2). To confirm the
presence of true in utero stress and PE features, we analyzed the AT1-AA and
NT-IgG injected mice. We discovered that pregnant mice injected with AT1-AA
had significant hypertension and renal damage, as reflected by microalbuminuria,
which resolved in the postpartum period (Fig. 2-3). Features of PE in the mouse
model resolved by postpartum day 10, corresponding to approximately week 12
of human postpartum periods, similar to the disappearance of features in human
PE pregnancies.
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Figure 17. Mean systolic pressure and microalbuminuria are significantly
increased in PE-IgG injected generation I mice but these features resolve in
the postpartum period.
(Left) In PE-IgG injected dams (Generation I), mean systolic pressure was
significantly increased in the antepartum period. This increased systolic pressure
resolved in the 10-day postpartum period, similar to human PE chronology. n = 45; * = p < 0.05. (Right) Similarly, microalbuminuria was significantly increased in
PE-IgG injected dams antepartum, but this increase in microalbuminuria was
attenuated in the postpartum period. n = 4-5; * = p < 0.05.
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Mice exposed to intrauterine stress demonstrate no phenotypic abnormalities
One of the key hallmark features of intrauterine stress is the presence of
intrauterine growth restriction and, possibly, fetal abnormality. It is wellestablished that intrauterine growth restriction results in features of prematurity
which often result in developmental delay organ-system specific abnormality. We
observed the pups born to the in utero stressed pregnancy and subsequent
generations. Because literature has noted a pup and litter size decrease in those
pregnancies affected by AT1-AA, we monitored the growth curve for significant
difference between the AT1-AA and control pups. Expectedly, we observed a
difference in male/female weights, but no significant difference in the growth
rates of pups born to AT1-AA affected mice or to subsequent pregnancies (Table
3).
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Table 3. Mouse growth curve and weight characteristics (g).
Male
Week 4

Generation II

Generation III

Female
Week 8

Week 4

Week 8

NT-IgG

PE-IgG

NT-IgG

PE-IgG

NT-IgG

PE-IgG

NT-IgG

PE-IgG

19.1 ±

18.06 ±

19.73 ±

19.60 ±

14.26 ±

17.06 ±

19.93 ±

19.91 ±

1.01

1.33

1.17

2.00

1.10

3.23

3.38

1.89

17.76 ±

19.46 ±

21.05 ±

20.12 ±

17.1 ±

17.9 ±

18.99 ±

20.56 ±

0.28

1.3

1.4

0.57

0.78

1.27

4.2

1.05
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Noting that the growth curves and litter sizes of the mice were similar, we
investigated whether mice born to affected pregnant mothers had alterations of
inflammatory and RAAS components as has been demonstrated in offspring of
stressed pregnancies. To determine this feature, we examined mRNA values of
various inflammatory markers and RAAS components via qRT-PCR from cDNA
isolated from the kidney of generation II mice. Through a qRT-PCR array of
kidney cDNA isolated after pup delivery, we found no difference in renin,
angiotensin converting enzyme, angiotensin II type II receptor, nor aldosterone
within the RAAS. We also found no difference in transcript levels of commonly
deranged inflammatory and vascular signaling components such as tumor
necrosis factor-alpha, endothelin-1, endothelin receptors A/B, nor endothelin
converting enzyme. These data indicate pups born to in utero stressed
environments experience no baseline derangements in terms of developmental
patterning, nor do they experience alterations within their various vascular and
inflammatory signaling pathways. However, these data do not completely explain
the increased incidence of adult-onset hypertension seen in adult progeny of in
utero stressed pregnancies in the absence of genetic factors. To reveal this
feature, we decided to investigate each generation of progeny with a provasoactive stimulus during the progeny adult period.
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Low-dose Angiotensin II (Ang II) results in significant systolic pressure increase
in progeny born exposed to in utero stress
While the data indicate that progeny born after exposure to in utero stress
are phenotypically normal, observational clinical literature has noted a significant
prevalence in adult-onset hypertension in the progeny which have been exposed
to intrauterine stress. To test this observation in our mouse model, we aged
progeny born from exposure to AT1-AA for 24 weeks before exposing them to a
low-dosage of Ang II (140 ng/kg/min)114 (Fig. 2-4).
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Figure 18. Schema of 24 week aging mouse model followed by low-dosage
Ang II infusion. Mean systolic pressure was monitored at regular intervals
during the experiment.
Mice born to both PE-IgG and NT-IgG injected mothers were aged for six months
and implanted with an osmostic minipump containing a low-dosage of Ang II (140
ng/kg/min). Blood pressure was measured after pump implantation on days 3, 7,
10, and 13. This same schema was used in the subsequent generation to
determine if this phenomena travels transgenerationally.
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Low-dosage Ang II is not thought to be a model of intrinsic renal damage,
however, the low-dosage is adequate to demonstrate an increased sensitivity to
a provasoactive stimulus. To verify that the aging process induced no significant
effect on mean systolic pressure, baseline blood pressures were taken at week
12 of aging. We demonstrated that mean systolic pressure is not affected by
aging at this early timepoint (Fig. 2-5).
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Figure19. Mean systolic blood pressure measured at week 12 indicated no
significant difference in mean systolic pressure.
Generation II mice showed no significant difference in mean systolic blood
pressure at week 12 after delivery. n = 6 mice
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To test Ang II sensitivity, microosmotic minipumps containing infusion dosages of
140 ng/kg/min were dorsally implanted into mice born after exposure to
intrauterine stress as well as control mice. During the period of implantation,
mean systolic pressure was monitored. Mice born from exposure to intrauterine
stressed environments show a significantly earlier elevation, as well as a
sustained elevation of mean systolic blood pressure as compared to control pups
(Fig. 2-6).

Figure 20. Low-dose Ang II resulted in more significant and earlier
elevation in mean systolic pressure in generation II mice.
Implantation of a microosmotic minipump infusing a low-dosage of Ang II
demonstrated that generation II mice born to PE-IgG infused dams had an earlier
and larger increase in mean systolic pressure from baseline than did mice born
to control dams. * = p < 0.05; 4-6 mice/group.
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These data indicate that pups born exposed to intrauterine stress lack
mechanisms to rectify increases in vascular tone. Moreover, to test that these
features are also present in subsequent generations, generation II is interbred to
produce generation III.
To test similar features in generation III, the same experimental plan was
followed, as previously described. Generation III mice were aged and measured
at midpoint through the aging period to determine if age had a significant effect
on baseline blood pressure. Baseline blood pressure measurements taken at
week 12 show no difference in mean systolic pressure between interbred
generation III mice (Fig 2-7).

82

Mean Systolic Blood
Pressure (mmHg)

150

100

50

G
PE
-Ig

N

TIg
G

0

Figure 21. Generation III mice showed no significant difference in mean
systolic pressure at week 12.
Similar to generation II, generation III mice show no difference in mean systolic
pressure at week 12. n = 6 mice
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Thus, at week 24 mice were implanted with a microosmotic minipump with a
dosage containing 140 ng/kg/min Ang II for infusion. Similar to generation II, mice
exposed to intrauterine stressed environments in a prior generation experience
an earlier and more significant increase in mean systolic pressure from baseline
after Ang II challenge than normal control mice (Fig. 2-8).
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Figure 22. Generation III mice experienced a more significant and earlier
increase in mean systolic pressure versus control mice.
Similar to generation II, generation III mice born to the lineage of stressed
pregnancies and subsequently exposed to Ang II have a significantly earlier and
sustained elevation of mean systolic pressure than control mice. * = p < 0.05; n =
6 mice/group
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These data indicate an interesting paradox—intrauterine stress in one generation
can prime future generations for increases in mean systolic pressure, given a
stressor. This increase in hypertension is difficult for the organism to rectify.
However, the mechanisms behind this increase in blood pressure and its
presence in subsequent generations has not been characterized.
Epigenetic modifications of the AT1R predispose increased AT1R expression
levels and hypertension
With a low-dosage of Ang II, we witnessed an increase in mean systolic
pressure in animals exposed to intrauterine stress. We witnessed this feature
propagating from the second to the third generation. However, the molecular
mechanism behind this increased hypertension is poorly characterized.
It is well-accepted in other research fields that epigenetic modifications are
responsible for features that are outside of the scope of genetic mutation. It is
thought that epigenetic mutations are responsible for many disease processes in
the fields of cancer and neurological conditions. Utilizing a genetically
homogenous mouse population, we are able to characterize epigenetic changes
in mice that examine changes to expression apart from genetic alteration.
To examine epigenetic changes within our mouse progeny, we utilized a
bisulfite PCR screening to examine the epigenetic modifications of promoter
regions of the AT1R. Because Ang II was used as the stimulus for the vasoactive
challenge, and in the absence of alterations of other RAAS and inflammatory
signaling factors, we looked to the AT1R as a likely candidate for modifications.
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We designed a sequence of primer sets to test the methylation content of CGrich sequences within the AT1R promoter region. This common technique
assesses the methylation content of cytosine residues within the gene promoter
region. Bisulfite sequencing revealed a significant hypomethylation of the
promoter region between 597-714 base pairs upstream from the transcription
start site in mice born from intrauterine stressed environments. Furthermore, this
hypomethylation is exacerbated by Ang II treatment. This finding suggests that
methylation patterns are imprinted during the intrauterine period and exposure to
Ang II results in further hypomethylation (Fig. 2-9).
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Figure 23. The AT1R promoter was hypomethylated in utero and further
hypomethylated with exposure to Ang II.
(Top panel) Five CpG primer pairs were designed based on promoter
sequencing prediction. Only a region between 597-714 bp upstream from the
transcription start site showed amplification. (Bottom panel) Bisulfite sequencing
revealed that the AT1R promoter region in generation II isolated renal tissue is
initially hypomethylated in utero prior to Ang II challenge. Hypomethylation is
further exacerbated by Ang II challenge. * = p < 0.05; 3-4 renal samples/group
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This pattern of hypomethylation has significant effects on AT1R expression.
AT1R expression is increased in pups exposed to intrauterine stress, but, this
difference is exacerbated by treatment with Ang II. This expression data was
confirmed by qRT-PCR and immunoblotting data from kidney cDNA and
membrane receptor isolation, respectively (Fig. 2-10).
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Figure 24. AT1R expression increased with Ang II exposure as confirmed by
qRT-PCR and immunoblotting.

(Top panel) AT1R mRNA expression in generation II indicated that expression of
AT1R initially is elevated in utero but is exacerbated by treatment with Ang II.
This expression level is confirmed by qRT-PCR. (Bottom panel) Representative
immunoblotting revealed that Ang II treatment increased expression levels of
AT1R from basal levels. * = p < 0.05; n = 3-4 renal sections/group
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Extending this hypothesis to the subsequent generations, we investigated
whether exposure to intrauterine stress had an effect the third generation. Thus,
we performed similar experiments on the third generation to test if the animals
had the same methylation patterns as the second generation. Bisulfite
sequencing showed that the AT1R promoter region was hypomethylated in the
same region as the second generation animals. Furthermore, in the presence of
Ang II stimulus, generation III animals exposed in their previous generation
experienced more significant hypomethylation in a key CG rich region as
opposed to control animals. Examining expression of AT1R, we witnessed a
higher expression of AT1R in generation III animals exposed to in utero stress.
This was exacerbated once again by exposure to Ang II stimulus (Fig. 2-11).
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Figure 25. AT1R specific methylation was decreased and AT1R expression
is increased as confirmed by qRT-PCR and immunoblotting in generation II
mice.
(Top left panel) Mice born to a lineage of in utero stress (generation III) display a
similar pattern of methylation as generation II. CpG island methylation is
decreased in utero prior to Ang II challenge, but displays a further decrease with
low-dose Ang II treatment. (Top right panel) Decreases in methylation precipitate
an increase in AT1R expression evident after treatment with Ang II as confirmed
by qRT-PCR. (Bottom panel) AT1R expression is elevated in mice born to in
utero stressed lineages. The AT1R expression is further exacerbated by
treatment with Ang II as confirmed by immunoblotting. * = p < 0.05
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These data suggest a key finding in the pathogenesis of vascular disorder
and the heritability of these features. We noted that sensitivity to a stimulus is
determined by amount of hypomethylation of the AT1R promoter region.
Furthermore, provasoactive stimulus causes significant hypomethylation of the
AT1R promoter. This hypomethylation activity has significant effects on gene
expression. Finally, these data suggest that all of these features can pass
through generations, implying that in utero insults in one generation can affect
development of future generations.
Hypomethylation of AT1R promoter region results in AP-1 transcriptional
activation
As reported in other literature, promoter modification can affect
transcriptional gene activation or repression by influencing the binding affinity of
transcription factors at key sites. To assess the degree of transcriptional binding
affinity, chromatin binding immunoprecipitation assays (ChIP) is frequently used.
These assays determine the binding efficiency of transcription factors in a
promoter sequence. Because of the observation of differential promoter
methylation in our mouse model, we decided to test the binding efficiency of
transcription factors in the hypomethylated promoter region.
Prior to designing targets for ChIP assay, we performed a blinded
sequence analysis on the hypomethylated promoter region. By BLAST analysis,
we determined that the c-Jun (AP-1) transcription factor had a predicted 88%
sequence

homology

with

the

hypomethylated

AT1R

promoter

region.
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Interestingly, AP-1 is extensively involved in growth factor, vascular factor, and
inflammatory factor signaling. Therefore, we decided to test the transcriptional
affinity of AP-1 with hypomethylated AT1R promoter sequences. Utilizing
crosslinking ChIP assays with chromatin isolated from the kidney of the
generation I mice, we found an increase in AP-1 binding to the hypomethylated
region of the AT1R prior to Ang II treatment. However, after Ang II treatment, we
observed a 2-fold increase in AP-1 activation and binding in the AT1R promoter
region. This indicates significant activation of AP-1 and a potential explanation
behind the increased expression of AT1R both in utero and after provasoactive
stimulus. We further extend these findings to generation III. Chromatin was
isolated from kidney tissue of interbred animals prior to treatment with Ang II and
subsequent to treatment.
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Figure 26. AP-1 transcription factor binding affinity is increased in
hypomethylated AT1R promoter regions.
(Top panel) Transcription factor prediction by PROMO analysis showed an 88%
sequence homology with a hypomethylated promoter sequence in the AT1R
promoter. (Left panel) XChIP assays crosslinking AP-1 transcription factor to
chromatin

segments

found

greater

AP-1

binding

and

amplification

of

hypomethylation AT1R promoter regions in generation II after Ang II treatment in
pups exposed to in utero stress. (Right panel) In pups born from lineages of in
utero stress (generation III), exposure to Ang II increases the binding of AP-1
transcription factor and subsequent amplification of specific hypomethylated
sequences of the AT1R promoter.
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Discussion
Presented here is the first mouse model to recapitulate the features of
adult-onset hypertension when primed with an in utero stress. Genetically
homogenous cohorts of mice were given IgG isolated from human patient
cohorts to represent a PE pregnant model or normal pregnancy. PE is associated
with hypertension and renal damage both in patients and in generation I of this
mouse

model.

Similar

to

patients,

PE

features

of

hypertension

and

microalbuminuria resolved in the murine postpartum period. In generation II, after
the mice were aged for 24 weeks and exposed to a vasoactive peptide (Ang II),
mice born from intrauterine stressed pregnancies were more susceptible to
hypertensive features. Mechanistically, consistent with current literature in
hypertensive disorders, we witnessed an activation of the RAAS with increased
sensitivity to Ang II stimuli. Interestingly, these data presented here offer a
unique two-hit mechanism to demonstrate how in utero stress precipitates
hypertensive feature in progeny. We established that aberrant promoter
methylation patterns occurring during intrauterine stressed environments can
predispose an organism to increased transcription of the AT1R gene and
receptor. This aberrant methylation pattern and increased transcription of RAAS
components increases sensitivity to environmental stimuli, and thus, increases
the chance for the organism to develop adult-onset hypertension. This new
paradigm stresses the importance of the intrauterine milieu as causative for
future development of disease in progeny. While the mechanism underlying
promoter methylation pattern changes is not addressed in this work, our data is
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consistent with other studies which also demonstrate decreased total methylation
in PE states.
In addition to methylation changes in direct progeny born from in utero
stressed environments, we also show that subsequent generations exhibit the
same aberrant methylation patterns within the RAAS. Previous studies have
demonstrated that epigenetic promoter methylation patterns can be transmitted
between generations and imprinted onto progeny DNA. Thus, methylation
patterns can affect subsequent generations genetic expression outside of genetic
modifications. Our data demonstrate these similar features. Generation III,
exhibits similarly decreased promoter methylation as the previous generation.
Therefore, similar features of hypertension exist within this generation upon
challenge with a vasoactive peptide.
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Figure 27. Working model of transgenerational passage of epigenetic
features.
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While we observe this two-hit hypothesis in our mouse model, we have
not investigated the mechanism behind the alteration of epigenetic patterning in
progeny nor the passage from one generation to the next. Some studies have
demonstrated the importance of S-adenosyl methionine and methyl transferases
as necessary for epigenetic alterations on the histone or promoter transcriptional
level. Studies have indicated that intracellular stress modulates the activity of
methyl transferase and the recycling of S-adenosyl homocysteine to S-adenosyl
methionine. Therefore, stressed conditions have the ability to decrease
methylated DNA within the promoter. Depending on the modification, this can
have activating or inhibiting consequences for genetic transcription. Future
studies will address how this pathway is modulated in times of intracellular or in
utero stress. These studies will have important ramifications for risk stratification
based on pregnancy status.
This study investigates the role of PE in the pathogenesis of adult-onset
hypertension. We posit a unique combination of decreased AT1R methylation
combined with increased expression of AT1R as instrumental in the activation of
the RAAS. Previous clinical data has implicated PE as an important risk factor
future cardiovascular risk. We also know that progeny born from intrauterine
stressed pregnancies also have increased cardiovascular risk. Based off of these
data, asking for familial incidence of PE may help us stratify a patient’s risk to
develop hypertension, stroke, or cardiovascular death. Furthermore, our study
also investigates a specific mechanism of upregulation of the AT1R. By
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assessing a patient’s promoter methylation patterns, clinicians would have a
picture of which messengers within the RAAS are altered. With further clinical
and epidemiological study, our data may lead to more personalized treatment of
hypertensive disorder and proper cardiovascular risk stratification.
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CHAPTER III: CONCLUSIONS AND FUTURE DIRECTIONS
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Disorders of hypertension during pregnancy present a unique challenge
as a healthcare issue. Decades of research have provided insights into the
pathogenesis of the disease; however, no definitive molecular process has
outlined the disease in totality. Furthermore, the lack of definitive mechanism has
also led to a lack of appropriate diagnostic tests to assess a mother’s chance to
develop preeclampsia or other hypertensive disorder of pregnancy. Finally, due
to the length of prospective studies, we are unaware of the effect that in utero
stress has on generations of progeny. Because of these problems, research in
the field of preeclampsia is vital to our understanding of the disease
pathogenesis and pregnancy, as a whole.
The studies presented here provide valuable insight into the pathogenesis
of PE as well as posit potential therapeutic targets and diagnostic exams to treat
and estimate a mother’s risk for disease development. The data confirming the
interplay between CRP, NKB and phosphocholine transferase, being well-known
possible factors inciting vascular damage, examines a new pathogenic
mechanism for PE. Moreover, the CRP-NKB-phosphocholine complex provides a
novel therapeutic target and potential diagnostic panel to predict and diagnose
PE prior to onset. Furthermore, the transgenerational mouse model is one of the
first studies to address the influence of in utero stress as a potential mechanism
of vascular genetic expression in a homogenous genetic population. The
implication for PE priming vascular damage through subsequent generations
provides an opportunity for progeny testing for hypertension risk.

102

The roles of CRP and NKB in the pathogenesis of PE have been
extensively hypothesized in earlier literature. However, this report was the first to
indicate that CRP acts as more than a nonspecific inflammatory mediator. We
present evidence that CRP can combine with a posttranslationally modified and
phosphocholinated NKB to activate the NK3R, a receptor instrumental in
hypertension. These data novelly indicate that the placenta was a contributory
source of CRP, and this excess production was instrumental in PE
symptomology. The placenta is vital in the production of PE features and key to
therapeutics.
In recent decades, the placental-fetal environment has become a potential
target for study in the heritability of PE and hypertensive disorders. While much
research

has

hypertension,

been
other

dedicated
mechanisms

to

investigating
have

been

genetic
less

causes

studied.

behind

Epigenetic

mechanisms of disease are thought to underlie many pathogenic processes.
Elucidation of epigenetic modifications could serve as prediction for adult-onset
hypertension. Additionally, epigenetic screening could lead to targeted therapy
for hypertensive disorder. By characterizing the epigenetic modification on
various promoters, we may be better to able screen for upregulated genes and
develop a targeted therapeutic to treat refractory hypertensive patients.
Furthermore, by studying in utero stress as it propagates through generations,
we can counsel women to avoid potential stressors, as they may affect their
intrauterine environment, and, ultimately their progeny.
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The novel data presented here posit a holistic view of preeclampsia,
hypertension, and hypertensive disorders of pregnancy. First, we have
demonstrated that acute inflammation and kinin signaling are integral in the
pathogenesis of PE. The molecular complex formation of CRP joining with posttranslationally modified NKB is essential to activation of the NK3R and production
of PE features. More importantly, the placenta is required for CRP-induced PE
features, as CRP has no effect in non-pregnant animals in the absence of
inflammatory stimulus. Inflammatory stress and activation of the kinin signaling
system leads to intrauterine stress, creating a malicious cycle harming the
mother and fetus. The fact that intrauterine stress has been noted as a potential
cause of developmental patterning dysfunction is an important clinical finding that
we have translated into our mouse model. We have demonstrated that acute
inflammation in the form of TNF-alpha superfamily members can induce
elevations of pathogenic autoantibodies against the AT1R. The presence of AT1AA in maternal circulation is positively correlated with PE features, IUGR, and,
thus, intrauterine stress. Through a multigenerational mouse model, we have
shown that intrauterine stress can initiate hypomethylation in the AT1R promoter,
and prime the developing fetus to development of hypertension. Further
exposure to a stress increases risk of hypertension development. Without
compensatory mechanisms, progeny are more sensitive to stimuli, and, thus,
develop hypertension more than progeny born to normal pregnancies. More
significantly, demehtyalted promoter regions are passed to future generations,
thus, predisposing a fetus in the absence of a direct fetal stress. These findings,
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in tandem, present numerous opportunities for preclinical diagnostics and
targeted therapy (Fig. 3-1).

Figure 28. Working model linking intrauterine stress to transgenerational
programming.
CRP-PC-NKB activation of the NK3R leads to pathogenic features of PE—
hypertension, renal damage, and sFlt-1 expression. The contribution of these to
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intrauterine stress can prime a developing fetus with hypomethylation of the
RAAS system and risk of hypertension after a late life exposure to environmental
stimulus.
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Future Directions
The data presented here reveal a comprehensive picture of the pathogenesis of
PE as well as offer explanations for transgenerational feature propagation.
However, even with intensive research efforts, neither the totality of PE
pathogenesis has not been elucidated, nor is research closer to finding effective
therapeutics and diagnostic assays. One significant finding to further investigate
is the value of assessing CRP and NKB prior to 20 weeks of gestation in our
pregnant cohort. Currently, human sera and plasma samples from the Combined
Antioxidant and Preeclampsia Prediction Study are available in various time
points both ante- and post-partum. These samples would be a valuable tool to
develop and test a diagnostic predictive clinical panel to predict the onset of PE.
Furthermore, this panel could become part of a woman’s routine clinical prenatal
exam.
In addition to PE prediction, our study also addressed fetal developmental
outcomes. We have demonstrated that epigenetic promoter modifications are
conserved throughout generation. According to available literature, peripheral
blood mononuclear cells provide an excellent tool for examining the
methylation/epigenetic portrait of a patient’s cells. By further characterizing the
methylation aberration within the patient’s cells, we would better be able to see
the effect of intrauterine stress on progeny, and estimate a conferred risk to
future generations. Furthermore, utilizing identified epigenetic markers, targeted
treatment options are more effective.

107

108

References
1.

Jacobs M, Nassar N, Roberts CL, Hadfield R, Morris JM, Ashton AW.
Levels of soluble fms-like tyrosine kinase one in first trimester and
outcomes of pregnancy: A systematic review. Reproductive biology and
endocrinology : RB&E. 2011;9:77

2.

Li F, Hagaman JR, Kim HS, Maeda N, Jennette JC, Faber JE,
Karumanchi SA, Smithies O, Takahashi N. Enos deficiency acts through
endothelin to aggravate sflt-1-induced pre-eclampsia-like phenotype. J Am
Soc Nephrol. 2012;23:652-660

3.

Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA,
Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukhatme VP,
Karumanchi SA. Excess placental soluble fms-like tyrosine kinase 1 (sflt1)
may contribute to endothelial dysfunction, hypertension, and proteinuria in
preeclampsia. J Clin Invest. 2003;111:649-658

4.

Levine RJ MS, Qian C, Lim K, England LJ, Yu KF, Schisterman EF,
Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi
SA. Circulating angiogenic factors and the risk of preeclampsia. New
England Journal of Medicine. 2004;350:672-683

5.

Jardim LL, Rios DR, Perucci LO, de Sousa LP, Gomes KB, Dusse LM. Is
the imbalance between pro-angiogenic and anti-angiogenic factors
associated with preeclampsia? Clinica chimica acta; international journal
of clinical chemistry. 2015;447:34-38

109

6.

Verlohren S, Herraiz I, Lapaire O, Schlembach D, Moertl M, Zeisler H,
Calda P, Holzgreve W, Galindo A, Engels T, Denk B, Stepan H. The sflt1/plgf ratio in different types of hypertensive pregnancy disorders and its
prognostic potential in preeclamptic patients. American journal of
obstetrics and gynecology. 2012;206:58 e51-58

7.

Derzsy Z, Prohaszka Z, Rigo J, Jr., Fust G, Molvarec A. Activation of the
complement system in normal pregnancy and preeclampsia. Molecular
immunology. 2010;47:1500-1506

8.

Regal JF, Gilbert JS, Burwick RM. The complement system and adverse
pregnancy outcomes. Molecular immunology. 2015;67:56-70

9.

Rampersad R, Barton A, Sadovsky Y, Nelson DM. The c5b-9 membrane
attack complex of complement activation localizes to villous trophoblast
injury in vivo and modulates human trophoblast function in vitro. Placenta.
2008;29:855-861

10.

Wang W, Irani RA, Zhang Y, Ramin SM, Blackwell SC, Tao L, Kellems
RE, Xia Y. Autoantibody-mediated complement c3a receptor activation
contributes to the pathogenesis of preeclampsia. Hypertension.
2012;60:712-721

11.

Penning M, Chua JS, van Kooten C, Zandbergen M, Buurma A, Schutte J,
Bruijn JA, Khankin EV, Bloemenkamp K, Karumanchi SA, Baelde H.
Classical complement pathway activation in the kidneys of women with
preeclampsia. Hypertension. 2015;66:117-125

110

12.

Conti E, Zezza L, Ralli E, Caserta D, Musumeci MB, Moscarini M, Autore
C, Volpe M. Growth factors in preeclampsia: A vascular disease model. A
failed vasodilation and angiogenic challenge from pregnancy onwards?
Cytokine & growth factor reviews. 2013;24:411-425

13.

Khankin EV, Mandala M, Colton I, Karumanchi SA, Osol G.
Hemodynamic, vascular, and reproductive impact of fms-like tyrosine
kinase 1 (flt1) blockade on the uteroplacental circulation during normal
mouse pregnancy. Biol Reprod. 2011

14.

Khalil RA GJ. Vascular mechanisms of increased arterial pressure in
preeclampsia: Lessons from animal models. Am J Physiol Regulatory
Integrative Comp Physiol. 2002:R29-R45

15.

Henao DE, Saleem MA. Proteinuria in preeclampsia from a podocyte
injury perspective. Current hypertension reports. 2013;15:600-605

16.

Matsubara K, Higaki T, Matsubara Y, Nawa A. Nitric oxide and reactive
oxygen species in the pathogenesis of preeclampsia. International journal
of molecular sciences. 2015;16:4600-4614

17.

Xu N, Chua AK, Jiang H, Liu NA, Goodarzi MO. Early embryonic
androgen exposure induces transgenerational epigenetic and metabolic
changes. Molecular endocrinology. 2014;28:1329-1336

18.

Martos SN, Tang WY, Wang Z. Elusive inheritance: Transgenerational
effects and epigenetic inheritance in human environmental disease. Prog
Biophys Mol Biol. 2015

111

19.

Leow MK. Environmental origins of hypertension: Phylogeny, ontogeny
and epigenetics. Hypertension research : official journal of the Japanese
Society of Hypertension. 2015;38:299-307

20.

Trerotola M, Relli V, Simeone P, Alberti S. Epigenetic inheritance and the
missing heritability. Human genomics. 2015;9:17

21.

Friso S, Carvajal CA, Fardella CE, Olivieri O. Epigenetics and arterial
hypertension: The challenge of emerging evidence. Translational research
: the journal of laboratory and clinical medicine. 2015;165:154-165

22.

Millis RM. Epigenetics and hypertension. Curr Hypertens Rep.
2011;13:21-28

23.

Gluckman PD HM, Cooper C, Thornburg KL. Effect of in utero and earlylife conditions on adult health and disease. NEJM. 2008;359:61-73

24.

Irani RA, Zhang Y, Blackwell SC, Zhou CC, Ramin SM, Kellems RE, Xia
Y. The detrimental role of angiotensin receptor agonistic autoantibodies in
intrauterine growth restriction seen in preeclampsia. J Exp Med.
2009;206:2809-2822

25.

Irani RA, Zhang Y, Zhou CC, Blackwell SC, Hicks MJ, Ramin SM, Kellems
RE, Xia Y. Autoantibody-mediated angiotensin receptor activation
contributes to preeclampsia through tumor necrosis factor-alpha signaling.
Hypertension. 2010;55:1246-1253

26.

Zhou CC, Irani RA, Dai Y, Blackwell SC, Hicks MJ, Ramin SM, Kellems
RE, Xia Y. Autoantibody-mediated il-6-dependent endothelin-1 elevation

112

underlies pathogenesis in a mouse model of preeclampsia. J Immunol.
2011;186:6024-6034
27.

Irani RA, Xia Y. The functional role of the renin-angiotensin system in
pregnancy and preeclampsia. Placenta. 2008;29:763-771

28.

Irani RA, Xia Y. Renin angiotensin signaling in normal pregnancy and
preeclampsia. Semin Nephrol. 2011;31:47-58

29.

Dhillion P, Wallace K, Herse F, Scott J, Wallukat G, Heath J, Mosely J,
Martin JN, Jr., Dechend R, Lamarca B. Il-17-mediated oxidative stress is
an important stimulator of at1-aa and hypertension during pregnancy. Am
J Physiol Regul Integr Comp Physiol. 2012;303:R353-358

30.

Gadonski G, LaMarca BB, Sullivan E, Bennett W, Chandler D, Granger
JP. Hypertension produced by reductions in uterine perfusion in the
pregnant rat: Role of interleukin 6. Hypertension. 2006;48:711-716

31.

LaMarca B, Parrish M, Ray LF, Murphy SR, Roberts L, Glover P, Wallukat
G, Wenzel K, Cockrell K, Martin JN, Jr., Ryan MJ, Dechend R.
Hypertension in response to autoantibodies to the angiotensin ii type i
receptor (at1-aa) in pregnant rats: Role of endothelin-1. Hypertension.
2009;54:905-909

32.

LaMarca B, Wallukat G, Llinas M, Herse F, Dechend R, Granger JP.
Autoantibodies to the angiotensin type i receptor in response to placental
ischemia and tumor necrosis factor alpha in pregnant rats. Hypertension.
2008;52:1168-1172

113

33.

LaMarca BB, Cockrell K, Sullivan E, Bennett W, Granger JP. Role of
endothelin in mediating tumor necrosis factor-induced hypertension in
pregnant rats. Hypertension. 2005;46:82-86

34.

Murphy SR, LaMarca BB, Parrish M, Cockrell K, Granger JP. Control of
soluble fms-like tyrosine-1 (sflt-1) production response to placental
ischemia/hypoxia: Role of tumor necrosis factor-alpha. Am J Physiol
Regul Integr Comp Physiol. 2013;304:R130-135

35.

Parrish MR, Murphy SR, Rutland S, Wallace K, Wenzel K, Wallukat G,
Keiser S, Ray LF, Dechend R, Martin JN, Granger JP, LaMarca B. The
effect of immune factors, tumor necrosis factor-alpha, and agonistic
autoantibodies to the angiotensin ii type i receptor on soluble fms-like
tyrosine-1 and soluble endoglin production in response to hypertension
during pregnancy. Am J Hypertens. 2010;23:911-916

36.

Parrish MR, Ryan MJ, Glover P, Brewer J, Ray L, Dechend R, Martin JN,
Jr., Lamarca BB. Angiotensin ii type 1 autoantibody induced hypertension
during pregnancy is associated with renal endothelial dysfunction. Gend
Med. 2011;8:184-188

37.

Parrish MR, Wallace K, Tam Tam KB, Herse F, Weimer A, Wenzel K,
Wallukat G, Ray LF, Arany M, Cockrell K, Martin JN, Dechend R, LaMarca
B. Hypertension in response to at1-aa: Role of reactive oxygen species in
pregnancy-induced hypertension. Am J Hypertens. 2011;24:835-840

38.

Cornelius DC, Hogg JP, Scott J, Wallace K, Herse F, Moseley J, Wallukat
G, Dechend R, LaMarca B. Administration of interleukin-17 soluble

114

receptor c suppresses th17 cells, oxidative stress, and hypertension in
response to placental ischemia during pregnancy. Hypertension.
2013;62:1068-1073
39.

LaMarca B, Cornelius D, Wallace K. Elucidating immune mechanisms
causing hypertension during pregnancy. Physiology. 2013;28:225-233

40.

Novotny S, Wallace K, Herse F, Moseley J, Darby M, Heath J, Gill J,
Wallukat G, Martin JN, Dechend R, LaMarca B. Cd4 t cells play a critical
role in mediating hypertension in response to placental ischemia. Journal
of hypertension : open access. 2013;2

41.

Labarrere CA, Zaloga GP. C-reactive protein: From innocent bystander to
pivotal mediator of atherosclerosis. Am J Med. 2004;117:499-507

42.

Pepys MB, Hirschfield GM, Tennent GA, Gallimore JR, Kahan MC, Bellotti
V, Hawkins PN, Myers RM, Smith MD, Polara A, Cobb AJ, Ley SV,
Aquilina JA, Robinson CV, Sharif I, Gray GA, Sabin CA, Jenvey MC,
Kolstoe SE, Thompson D, Wood SP. Targeting c-reactive protein for the
treatment of cardiovascular disease. Nature. 2006;440:1217-1221

43.

Verma S, Wang CH, Li SH, Dumont AS, Fedak PW, Badiwala MV, Dhillon
B, Weisel RD, Li RK, Mickle DA, Stewart DJ. A self-fulfilling prophecy: Creactive protein attenuates nitric oxide production and inhibits
angiogenesis. Circulation. 2002;106:913-919

44.

Boij R, Svensson J, Nilsson-Ekdahl K, Sandholm K, Lindahl TL, Palonek
E, Garle M, Berg G, Ernerudh J, Jenmalm M, Matthiesen L. Biomarkers of

115

coagulation, inflammation, and angiogenesis are independently
associated with preeclampsia. Am J Reprod Immunol. 2012;68:258-270
45.

Guo F, Liu JT, Wang CJ, Pang XM. Pravastatin inhibits c-reactive protein
generation induced by fibrinogen, fibrin and fdp in isolated rat vascular
smooth muscle cells. Inflamm Res. 2012;61:127-134

46.

Shlipak MG. Elevations of inflammatory and procoagulant biomarkers in
elderly persons with renal insufficiency. Circulation. 2002;107:87-92

47.

Catarino C, Santos-Silva A, Belo L, Rocha-Pereira P, Rocha S, Patricio B,
Quintanilha A, Rebelo I. Inflammatory disturbances in preeclampsia:
Relationship between maternal and umbilical cord blood. J Pregnancy.
2012;2012:684384

48.

Ertas IE, Kahyaoglu S, Yilmaz B, Ozel M, Sut N, Guven MA, Danisman N.
Association of maternal serum high sensitive c-reactive protein level with
body mass index and severity of pre-eclampsia at third trimester. J Obstet
Gynaecol Res. 2010;36:970-977

49.

Grill S, Rusterholz C, Zanetti-Dallenbach R, Tercanli S, Holzgreve W,
Hahn S, Lapaire O. Potential markers of preeclampsia--a review.
Reproductive biology and endocrinology : RB&E. 2009;7:70

50.

Castellano G, Di Vittorio A, Dalfino G, Loverre A, Marrone D, Simone S,
Schena FP, Pertosa G, Grandaliano G. Pentraxin 3 and complement
cascade activation in the failure of arteriovenous fistula. Atherosclerosis.
2010;209:241-247

116

51.

Cetin I, Cozzi V, Papageorghiou AT, Maina V, Montanelli A, Garlanda C,
Thilaganathan B. First trimester ptx3 levels in women who subsequently
develop preeclampsia and fetal growth restriction. Acta Obstet Gynecol
Scand. 2009;88:846-849

52.

Larsson A, Palm M, Helmersson J, Axelsson O. Pentraxin 3 values during
normal pregnancy. Inflammation. 2011;34:448-451

53.

Reimer T, Rohrmann H, Stubert J, Pecks U, Glocker MO, Richter DU,
Gerber B. Angiogenic factors and acute-phase proteins in serum samples
of preeclampsia and hellp patients: A matched-pair analysis. The journal
of maternal-fetal & neonatal medicine : the official journal of the European
Association of Perinatal Medicine, the Federation of Asia and Oceania
Perinatal Societies, the International Society of Perinatal Obstet.
2013;26:263-269

54.

Kashanian M, Aghbali F, Mahali N. Evaluation of the diagnostic value of
the first-trimester maternal serum high-sensitivity c-reactive protein level
for prediction of pre-eclampsia. The journal of obstetrics and gynaecology
research. 2013;39:1549-1554

55.

Thilaganathan B WB, Zanardini C, Sheldon J,, Ralph E PA. Earlypregnancy multiple serum markers and second-trimester uterine artery
doppler in predicting preeclampsia. ACOG. 2010;115:1233-1238

56.

Page NM. Neurokinin b and pre-eclampsia: A decade of discovery.
Reproductive biology and endocrinology : RB&E. 2010;8:4

117

57.

Page NM, Woods RJ, Gardiner SM, Lomthaisong K, Gladwell RT, Butlin
DJ, Manyonda IT, Lowry PJ. Excessive placental secretion of neurokinin b
during the third trimester causes pre-eclampsia. Nature. 2005;405:797800

58.

Zulfikaroglu E, Ugur M, Taflan S, Ugurlu N, Atalay A, Kalyoncu S.
Neurokinin b levels in maternal and umbilical cord blood in preeclamptic
and normal pregnancies. J Perinat Med. 2007;35:200-202

59.

Grant AD, Akhtar R, Gerard NP, Brain SD. Neurokinin b induces oedema
formation in mouse lung via tachykinin receptor-independent mechanisms.
J Physiol. 2002;543:1007-1014

60.

Lowry P. 1-o-alkenyl-sn-glyceryl-3-phosphorylcholine may be a novel
posttranslational modification used by the placenta. Biopolymers.
2011;96:189-192

61.

Geissbuehler V, Moser R, Zimmermann K, Hillermann R, Czarniecki J,
Gebhardt SG, Eberhard J. Altered plasma neurokinin b levels in patients
with pre-eclampsia. Arch Gynecol Obstet. 2007;276:151-157

62.

Arocho A CB, Ladanyi M, Pan Q. Validation of the 2-ddct calculation as an
alternative method of data analysis for quantitative pcr of bcr-abl p210
transcripts. Diagn Mol Pathol. 2006;15:56-61

63.

Zhang W, Wang W, Yu H, Zhang Y, Dai Y, Ning C, Tao L, Sun H, Kellems
RE, Blackburn MR, Xia Y. Interleukin 6 underlies angiotensin ii-induced
hypertension and chronic renal damage. Hypertension. 2012;59:136-144

118

64.

Wang W, Parchim NF, Iriyama T, Luo R, Zhao C, Liu C, Irani RA, Zhang
W, Ning C, Zhang Y, Blackwell SC, Chen L, Tao L, Hicks MJ, Kellems RE,
Xia Y. Excess light contributes to placental impairment, increased
secretion of vasoactive factors, hypertension, and proteinuria in
preeclampsia. Hypertension. 2014;63:595-606

65.

Nakada E, Walley KR, Nakada T, Hu Y, von Dadelszen P, Boyd JH. Tolllike receptor-3 stimulation upregulates sflt-1 production by trophoblast
cells. Placenta. 2009;30:774-779

66.

Agarwal I, Karumanchi SA. Preeclampsia and the anti-angiogenic state.
Pregnancy Hypertens. 2011;1:17-21

67.

Ikeda T, Sun L, Tsuruoka N, Ishigaki Y, Yoshitomi Y, Yoshitake Y,
Yonekura H. Hypoxia down-regulates sflt-1 (svegfr-1) expression in
human microvascular endothelial cells by a mechanism involving mrna
alternative processing. Biochem J. 2011;436:399-407

68.

Jebbink J, Keijser R, Veenboer G, van der Post J, Ris-Stalpers C, Afink G.
Expression of placental flt1 transcript variants relates to both gestational
hypertensive disease and fetal growth. Hypertension. 2011;58:70-76

69.

Youssef A, Righetti F, Morano D, Rizzo N, Farina A. Uterine artery doppler
and biochemical markers (papp-a, pigf, sflt-1, p-selectin, ngal) at 11 + 0 to
13 + 6 weeks in the prediction of late (> 34 weeks) pre-eclampsia. Prenat
Diagn. 2011;31:1141-1146

70.

Grad E, Danenberg HD. C-reactive protein and atherothrombosis: Cause
or effect? Blood Rev. 2013;27:23-29

119

71.

Nillawar AN, Joshi KB, Patil SB, Bardapurkar JS, Bardapurkar SJ.
Evaluation of hs-crp and lipid profile in copd. J Clin Diagn Res.
2013;7:801-803

72.

Christian LM, Porter K. Longitudinal changes in serum proinflammatory
markers across pregnancy and postpartum: Effects of maternal body
mass index. Cytokine. 2014

73.

Horsburgh S R-AP, Adams R, Smith C. Exercise and inflammation-related
epigenetic modifications: Focus on DNA methylation. Exerc Immunol Rev.
2015;21:26-41

74.

Godfrey KM, Gluckman PD, Hanson MA. Developmental origins of
metabolic disease: Life course and intergenerational perspectives. Trends
in endocrinology and metabolism: TEM. 2010;21:199-205

75.

Liu Y, Hoyo C, Murphy S, Huang Z, Overcash F, Thompson J, Brown H,
Murtha AP. DNA methylation at imprint regulatory regions in preterm birth
and infection. American journal of obstetrics and gynecology.
2013;208:395 e391-397

76.

Szyf M. Nongenetic inheritance and transgenerational epigenetics. Trends
in molecular medicine. 2015;21:134-144

77.

Van Soom A, Peelman L, Holt WV, Fazeli A. An introduction to
epigenetics as the link between genotype and environment: A personal
view. Reproduction in domestic animals = Zuchthygiene. 2014;49 Suppl
3:2-10

120

78.

Rauch T, Pfeifer GP. Methylated-cpg island recovery assay: A new
technique for the rapid detection of methylated-cpg islands in cancer.
Laboratory investigation; a journal of technical methods and pathology.
2005;85:1172-1180

79.

Rivière G, Lienhard D, Andrieu T, Vieau D, Frey BM, Frey FJ. Epigenetic
regulation of somatic angiotensin-converting enzyme by DNA methylation
and histone acetylation. Epigenetics : official journal of the DNA
Methylation Society. 2014;6:478-489

80.

Wang Y XS, Cao Y, Xie Z, Lai C, Ji X, Bi J. Folate deficiency exacerbates
apoptosis by inducing hypomethylation and resultant overexpression of
dr4 together with altering dnmts in alzheimer’s disease. Int J Clin Exp
Med. 2014;7:1945-1957

81.

Hamidi T SA, Chen T. Genetic alterations of DNA methylation machinery
in human diseases. Epigenomics. 2015;7:247-265

82.

Bellamy L, Casas JP, Hingorani AD, Williams DJ. Pre-eclampsia and risk
of cardiovascular disease and cancer in later life: Systematic review and
meta-analysis. Bmj. 2007;335:974

83.

Lazdam M, de la Horra A, Diesch J, Kenworthy Y, Davis E, Lewandowski
AJ, Szmigielski C, Shore A, Mackillop L, Kharbanda R, Alp N, Redman C,
Kelly B, Leeson P. Unique blood pressure characteristics in mother and
offspring after early onset preeclampsia. Hypertension. 2012;60:13381345

121

84.

Lin S, Leonard D, Co MA, Mukhopadhyay D, Giri B, Perger L, Beeram
MR, Kuehl TJ, Uddin MN. Pre-eclampsia has an adverse impact on
maternal and fetal health. Translational research : the journal of laboratory
and clinical medicine. 2014

85.

Davis EF, Lazdam M, Lewandowski AJ, Worton SA, Kelly B, Kenworthy Y,
Adwani S, Wilkinson AR, McCormick K, Sargent I, Redman C, Leeson P.
Cardiovascular risk factors in children and young adults born to
preeclamptic pregnancies: A systematic review. Pediatrics.
2012;129:e1552-1561

86.

Fraser A, Nelson SM, Macdonald-Wallis C, Sattar N, Lawlor DA.
Hypertensive disorders of pregnancy and cardiometabolic health in
adolescent offspring. Hypertension. 2013;62:614-620

87.

Kajantie E, Eriksson JG, Osmond C, Thornburg K, Barker DJ. Preeclampsia is associated with increased risk of stroke in the adult offspring:
The helsinki birth cohort study. Stroke; a journal of cerebral circulation.
2009;40:1176-1180

88.

Miettola S, Hartikainen AL, Vaarasmaki M, Bloigu A, Ruokonen A, Jarvelin
MR, Pouta A. Offspring's blood pressure and metabolic phenotype after
exposure to gestational hypertension in utero. European journal of
epidemiology. 2013;28:87-98

89.

Padmanabhan N, Jia D, Geary-Joo C, Wu X, Ferguson-Smith AC, Fung E,
Bieda MC, Snyder FF, Gravel RA, Cross JC, Watson ED. Mutation in

122

folate metabolism causes epigenetic instability and transgenerational
effects on development. Cell. 2013;155:81-93
90.

Bracewell MA, Hennessy EM, Wolke D, Marlow N. The epicure study:
Growth and blood pressure at 6 years of age following extremely preterm
birth. Archives of disease in childhood. Fetal and neonatal edition.
2008;93:F108-114

91.

Ferreira I, Peeters LL, Stehouwer CD. Preeclampsia and increased blood
pressure in the offspring: Meta-analysis and critical review of the
evidence. Journal of hypertension. 2009;27:1955-1959

92.

Geelhoed JJ, Fraser A, Tilling K, Benfield L, Davey Smith G, Sattar N,
Nelson SM, Lawlor DA. Preeclampsia and gestational hypertension are
associated with childhood blood pressure independently of family
adiposity measures: The avon longitudinal study of parents and children.
Circulation. 2010;122:1192-1199

93.

Libby G, Murphy DJ, McEwan NF, Greene SA, Forsyth JS, Chien PW,
Morris AD, Collaboration DM. Pre-eclampsia and the later development of
type 2 diabetes in mothers and their children: An intergenerational study
from the walker cohort. Diabetologia. 2007;50:523-530

94.

Oglaend B, Forman MR, Romundstad PR, Nilsen ST, Vatten LJ. Blood
pressure in early adolescence in the offspring of preeclamptic and
normotensive pregnancies. Journal of hypertension. 2009;27:2051-2054

123

95.

Ophir E, Dourleshter G, Hirsh Y, Fait V, German L, Bornstein J. Newborns
of pre-eclamptic women: A biochemical difference present in utero. Acta
obstetricia et gynecologica Scandinavica. 2006;85:1172-1178

96.

Palmsten K, Buka SL, Michels KB. Maternal pregnancy-related
hypertension and risk for hypertension in offspring later in life. Obstetrics
and gynecology. 2010;116:858-864

97.

Tenhola S, Rahiala E, Martikainen A, Halonen P, Voutilainen R. Blood
pressure, serum lipids, fasting insulin, and adrenal hormones in 12-yearold children born with maternal preeclampsia. The Journal of clinical
endocrinology and metabolism. 2003;88:1217-1222

98.

Vatten L. Intrauterine exposure to preeclampsia and adolescent blood
pressure, body size, and age at menarche in female offspring. Obstetrics
& Gynecology. 2003;101:529-533

99.

Mirabito KM, Hilliard LM, Wei Z, Tikellis C, Widdop RE, Vinh A, Denton
KM. Role of inflammation and the angiotensin type 2 receptor in the
regulation of arterial pressure during pregnancy in mice. Hypertension.
2014;64:626-631

100.

Pulgar VM, Yamaleyeva LM, Varagic J, McGee CM, Bader M, Dechend R,
Howlett AC, Brosnihan KB. Increased angiotensin ii contraction of the
uterine artery at early gestation in a transgenic model of hypertensive
pregnancy is reduced by inhibition of endocannabinoid hydrolysis.
Hypertension. 2014;64:619-625

124

101.

Sanghavi M, Rutherford JD. Cardiovascular physiology of pregnancy.
Circulation. 2014;130:1003-1008

102.

Tkachenko O, Shchekochikhin D, Schrier RW. Hormones and
hemodynamics in pregnancy. International journal of endocrinology and
metabolism. 2014;12:e14098

103.

Mendoza A LE. The compensatory renin–angiotensin system in the
central regulation of arterial pressure: New avenues and new challenges.
Therapeutic Advances in Cardiovascular Disease. 2015;Epub:1-8

104.

Danyel LA, Schmerler P, Paulis L, Unger T, Steckelings UM. Impact of
at2-receptor stimulation on vascular biology, kidney function, and blood
pressure. Integrated blood pressure control. 2013;6:153-161

105.

Chappell MC. Nonclassical renin-angiotensin system and renal function.
Comprehensive Physiology. 2012;2:2733-2752

106.

Saxena AR, Karumanchi SA, Brown NJ, Royle CM, McElrath TF, Seely
EW. Increased sensitivity to angiotensin ii is present postpartum in women
with a history of hypertensive pregnancy. Hypertension. 2010;55:12391245

107.

Wenzel K, Rajakumar A, Haase H, Geusens N, Hubner N, Schulz H,
Brewer J, Roberts L, Hubel CA, Herse F, Hering L, Qadri F, Lindschau C,
Wallukat G, Pijnenborg R, Heidecke H, Riemekasten G, Luft FC, Muller
DN, Lamarca B, Dechend R. Angiotensin ii type 1 receptor antibodies and
increased angiotensin ii sensitivity in pregnant rats. Hypertension.
2011;58:77-84

125

108.

van der Graaf AM, Wiegman MJ, Plosch T, Zeeman GG, van Buiten A,
Henning RH, Buikema H, Faas MM. Endothelium-dependent relaxation
and angiotensin ii sensitivity in experimental preeclampsia. PloS one.
2013;8:e79884

109.

Wang F, Demura M, Cheng Y, Zhu A, Karashima S, Yoneda T, Demura Y,
Maeda Y, Namiki M, Ono K, Nakamura Y, Sasano H, Akagi T, Yamagishi
M, Saijoh K, Takeda Y. Dynamic ccaat/enhancer binding proteinassociated changes of DNA methylation in the angiotensinogen gene.
Hypertension. 2014;63:281-288

110.

McMinn J, Wei M, Schupf N, Cusmai J, Johnson EB, Smith AC, Weksberg
R, Thaker HM, Tycko B. Unbalanced placental expression of imprinted
genes in human intrauterine growth restriction. Placenta. 2006;27:540-549

111.

Siddiqui AH, Irani RA, Blackwell SC, Ramin SM, Kellems RE, Xia Y.
Angiotensin receptor agonistic autoantibody is highly prevalent in
preeclampsia: Correlation with disease severity. Hypertension.
2010;55:386-393

112.

Liu C, Wang W, Parchim N, Irani RA, Blackwell SC, Sibai B, Jin J, Kellems
RE, Xia Y. Tissue transglutaminase contributes to the pathogenesis of
preeclampsia and stabilizes placental angiotensin receptor type 1 by
ubiquitination-preventing isopeptide modification. Hypertension.
2014;63:353-361

126

113.

Herman JG GJ, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific
pcr: A novel pcr assay for methylation status of cpg islands. PNAS.
1996:9821-9826

114.

Saleh MA, McMaster WG, Wu J, Norlander AE, Funt SA, Thabet SR,
Kirabo A, Xiao L, Chen W, Itani HA, Michell D, Huan T, Zhang Y, Takaki
S, Titze J, Levy D, Harrison DG, Madhur MS. Lymphocyte adaptor protein
lnk deficiency exacerbates hypertension and end-organ inflammation. The
Journal of clinical investigation. 2015;125:1189-1202

127

Vita
Nicholas Farrell Parchim was born in McComb, MS on April 13, 1986 to Nyle
Francis Parchim and Elizabeth Menghini Parchim. After completing high school
at Louisiana School for Math, Science, and the Arts, he enrolled at Loyola
University in New Orleans, LA. He graduated summa cum laude in May 2008,
receiving a bachelor of science degree in biological sciences-chemistry. In June
2008, he entered the MD/PhD program at University of Texas-Houston Health
Science Center. He completed three years of medical education before
beginning his PhD studies in Dr. Yang Xia’s laboratory in the Department of
Biochemistry at the UT-Health Graduate School of Biomedical Sciences.

128

